Introduction {#s1}
============

The genome has been classically viewed as being constant from cell to cell in the same individual, with genomic differences passed on through the germline. However, within neurons of the brain, numerous studies have reported somatic variability producing complex genomic mosaicism but having unknown function. Identified forms of somatically arising genomic mosaicism include aneuploidy (reviewed in [@bib9]), LINE elements ([@bib48]; [@bib2]; [@bib21]), copy number variations (CNVs) ([@bib28]; [@bib45]; [@bib11]), and DNA content variation (DCV) ([@bib76]; [@bib23]).

AD is the most common form of dementia and is characterized by the presence of amyloid plaques, synaptic loss, and cell death ([@bib1]), notably affecting the prefrontal cortex. The major component of these plaques is β-amyloid (Aβ), a protein encoded by *APP* ([@bib27]; [@bib66]; [@bib71]). Familial AD accounts for less than 5% of all cases and has been genetically linked to mutations in *APP* and two presenilins (PSEN), PSEN1 and PSEN2, the catalytic components of γ-secretase and the units responsible for cleavage of APP ([@bib57]; [@bib4]). In addition, *APP* gene dosage is strongly associated with AD pathogenesis based on multiple lines of evidence. First, Down syndrome (DS), with three copies of *APP*, produces neuropathology virtually identical to AD ([@bib26]; [@bib17]) and *APP* locus duplications are sufficient to cause familial AD ([@bib63]; [@bib64]; [@bib46]). Moreover, AD-protective effects have been reported in DS with *APP* deletion via partial trisomy ([@bib56]), as well as in familial AD with an *APP* partial loss-of-function mutation ([@bib38]). However, seminal studies in the 1980s failed to detect evidence of *APP* amplification in sporadic Alzheimer\'s disease peripheral blood and whole brain ([@bib54]; [@bib67]; [@bib72]) despite strong linkage in familial AD, thus linkage between sporadic AD and *APP* remains unclear*.*

The existence of region specific genomic mosaicism in the normal brain ([@bib75]) raised the possibility that DCV, defined as variations in the total DNA amount present in a single cell or population, might play a functional role in sporadic brain diseases by altering pathogenic loci in individual cells. The validated pathogenicity of *APP* in familial AD suggested that mosaic alterations in *APP* copy number within single neurons may play a role in producing sporadic AD. Through the use of five independent experimental approaches, we report increased somatic genomic variation within individual sporadic AD neurons involving mosaic increases in both DNA content and *APP* copy number.

Results {#s2}
=======

Methodologies to identify genomic mosaicism in AD brain nuclei utilized multiple independent approaches ([Figure 1](#fig1){ref-type="fig"}). First, neuronal nuclei were isolated from paired prefrontal cortex and cerebellum of postmortem human brains as previously described ([Figure 1A](#fig1){ref-type="fig"}) ([@bib75], [@bib76]). Nuclei were analyzed for: DNA content changes ([Figure 1B](#fig1){ref-type="fig"}), *APP* CNVs using qPCR in small populations ([Figure 1C](#fig1){ref-type="fig"}) and single-nuclei ([Figure 1D](#fig1){ref-type="fig"}), trisomy 21 using standard fluorescence in situ hybridization (FISH) ([Figure 1E](#fig1){ref-type="fig"}), and amplified *APP* loci using PNA-FISH ([Figure 1F](#fig1){ref-type="fig"}).10.7554/eLife.05116.003Figure 1.Methodologies used in assessing genomically mosaic AD.(**A**) Neuronal nuclei were isolated from the prefrontal cortex and cerebellum of postmortem human brain (see 'Materials and methods' for samples used) as described ([@bib75]). (**B**) Nuclear DNA was stained with propidium iodide (PI) and DNA content was quantified using flow cytometric analysis. (**C**) *APP* copy number variations were analyzed in small populations of nuclei (∼75 genomes) using custom primers for exon 14 of *APP*. (**D**) Single-cell qPCR assessed *APP* copy number variations in individual neuronal nuclei via TaqMan probes and a modified Biomark integrated fluidic chip system (Fluidigm Corporation, South San Francisco). (**E**) FISH paints against the whole q arm of chromosome 21 and a point probe against a region on the q arm of 21 (21q22.13-q22.2) were used to double-label and call aneusomies in AD samples. (**F**) Peptide nucleic acid (PNA) FISH was combined with super resolution microscopy for threshold detection of *APP* copy number above ∼2 occurring at a single locus.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.003](10.7554/eLife.05116.003)

AD cortices show increased DNA content variation (DCV) {#s2-1}
------------------------------------------------------

Previous work identified DNA content changes with regional variability in the non-diseased brain, where prefrontal cortical nuclei---particularly neuronal nuclei---displayed increased DCV compared to nuclei of the cerebellum and non-brain controls ([@bib76]). The current study utilizes the same techniques for DNA content analysis by flow cytometry using propidium iodide (PI). PI staining is the predominant methodology for quantitatively differentiating nuclei or cells with variable DNA content and is routinely utilized as a gold standard in multiple fields including genomic comparisons across species in botany ([@bib19]), studies of the cell cycle ([@bib40]), and DNA degradation produced by apoptosis ([@bib62]). Prior analyses ruled out the effects of DNA dyes, nuclear size, mitochondrial contamination, and autofluorescent lipofuscin on DNA content and validated genomic increases in DNA content using quantitation of CENP-B PNA probes against human centromere repeats ([@bib76]) which have been further substantiated by identification of copy number gains in single human neurons ([@bib28]; [@bib45]).

To further validate DCV in human neurons, whole genome amplification (WGA) was used on cortical neuronal nuclei sorted into populations of high or low DNA content based upon PI intensity. Nuclei with high or low DNA content were sorted into 12 replicates of 1000, 500, or 100 and were then subject to DNA content assessment by WGA to assess starting amounts of DNA template in each sample ([Figure 2A](#fig2){ref-type="fig"}). Nuclei were denatured and amplified by multiple displacement amplification (MDA) during which DNA synthesis was continually measured by SYBR Green fluorescence ([Figure 2B](#fig2){ref-type="fig"}). In every case, nuclei with high PI intensity also showed increased DNA synthesis over those with low PI intensity. These results independently confirm, as expected, that PI staining intensity faithfully reports DNA content.10.7554/eLife.05116.004Figure 2.AD cortical nuclei show increased DNA content variation (DCV) by flow cytometry.(**A**) Histogram displaying gating parameters used in sorting 'high' and 'low' DNA content populations for validation of DNA content. (**B**) Validation of DNA content analyses using semi-quantitative MDA whole-genome amplification (WGA) on 'high' and 'low' DNA content populations of 1000, 500, and 100 nuclei. (**C** and **D**) Representative DNA content histograms for lymphocytes (LYM), AD cerebellum (CBL), and AD prefrontal cortex (CTX). Each colored histogram represents a separate sample in each set; CTX and CBL samples are from paired brains. Chicken erythrocyte nuclei (CEN) were used as internal calibration controls. (**E**) Representative orthogonal view of DNA content vs forward scatter width (FSC-W). For each brain sample, the area to the right of the vertical line indicates a DNA content increase of the population of nuclei. AD-6 CTX is a representative right-hand peak shift and AD-7 is a representative right-hand shoulder (see [Figure 3A](#fig3){ref-type="fig"} for more examples). (**F**) DNA content changes for all human LYM, ND, and AD brain samples examined (AD CTX N = 32, AD CBL N = 16, LYM N = 15 \[20 meta analysis\], ND CTX = 21 \[36 meta analysis\], ND CBL = 11 \[12 meta analysis\]). Red bars denote average for each group relative to lymphocytes. Averages are as follows (including metadata from [@bib76]): AD CTX 8.219%; AD CBL −0.1104%; LYM −0.2915%; ND CTX 2.239%; ND CBL −3.358%. (**G**) DNA content changes of the current study (AVOVA p \< 0.0001). (**H**) DNA content changes of the current study combined with metadata from [@bib76] (ANOVA p \< 0.0001). (**I**) Comparison of mean coefficient of variation (CV statistic from FlowJo of the population, included metadata from [@bib76]) demonstrates that there is an average increase in the variation of AD samples (ANOVA p \< 0.0001). \*p = 0.05, \*\*p = 0.01, \*\*\*p = 0.001, \*\*\*\*p \< 0.0001, See [Figure 2---source data 1](#SD1-data){ref-type="supplementary-material"} for exact p values. See [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} for age, PMI and Braak score correlations. See [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"} for control of nuclear size analysis.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.004](10.7554/eLife.05116.004)10.7554/eLife.05116.005Figure 2---source data 1.DNA Index (DI) and percent change values and statistics.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.005](10.7554/eLife.05116.005)10.7554/eLife.05116.006Figure 2---figure supplement 1.DNA content shows no correlation with age or post-mortem index (PMI).(**A**) Comparison of mean skew values for each sample group, skew determined as: (Mean − Mode/Standard Deviation of the diploid DNA content peak). (**B**) No correlation was observed between DNA content and Braak score. (**C**--**E**) No correlation was observed between DNA content and age across all brains analyzed. (**F**--**H**) No correlation was observed between DNA content and post-mortem index across all brains analyzed.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.006](10.7554/eLife.05116.006)10.7554/eLife.05116.007Figure 2---figure supplement 2.Analysis of nuclear size and DNA content.(**A**--**C**) Representative flow cytometry scatter plots of nuclei. (**A**) Lymphocytes (LYM), (**B**) CTX nuclei, (**C**) CBL nuclei. (**D**) Overlay of red boxes shown in (**A**--**C**), demonstrating that cortical nuclei similar in size to LYM and CBL consistently display a DNA content shift.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.007](10.7554/eLife.05116.007)

AD neuropathology strongly affects the prefrontal cortex. We therefore first interrogated the DNA content of pathologically confirmed prefrontal cortices (N = 32), using previously described methodologies for DCV analyses in neuronal nuclei ([Figure 1B](#fig1){ref-type="fig"}) ([@bib76]). In control experiments, AD cerebellar nuclei showed DNA content profiles similar to lymphocytes, characterized by histograms with sharp peaks and narrow bases ([Figure 2C,E](#fig2){ref-type="fig"}). By comparison, AD cortices displayed high variability characterized by right hand shoulders ([Figure 2D,E](#fig2){ref-type="fig"} \[AD-7\]), large right hand peak shifts ([Figure 2D,E](#fig2){ref-type="fig"} \[AD-6\]), and wide bases. Of the AD cortex samples examined, greater than 90% displayed a net DNA content increase, averaging approximately 8% gain over human lymphocyte controls ([Figure 2F--H](#fig2){ref-type="fig"}). Notably, the AD cortex displayed increases beyond those observed in non-diseased cortices, with an average gain of approximately 6% over age and sex-matched samples ([Figure 2F--H](#fig2){ref-type="fig"}). AD cortices also displayed an increased coefficient of variation over non-diseased cortical nuclei and all cerebellar nuclei ([Figure 2I](#fig2){ref-type="fig"}) as well as a consistent skewed distribution compared to AD cerebellum ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). In addition, we examined 14 paired sets of AD cortex and cerebellum from the same individual ([Figure 3A](#fig3){ref-type="fig"}) and 12 paired sets from non-diseased individuals ([Figure 3B](#fig3){ref-type="fig"}). Each AD cortex showed unique cortical histograms and increases in total cortical DNA compared to the cerebellum. In AD and non-diseased brain samples, DNA content changes did not correlate with age, Braak score, or postmortem index ([Figure 2---figure supplement 1B--H](#fig2s1){ref-type="fig"}), and DNA content was independent of nuclear size ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) ([@bib76]). Importantly, the increase observed was significantly less than a 4N tetraploid genome (∼12,800 Mb), yet significantly more than what would be expected from a hypersomy of even the largest chromosome (chr1: ∼250 Mb or 3.9%). These results indicate that neuroanatomically selective increases in DNA content represent a distinct, reproducible, and prevalent characteristic of the AD brain.10.7554/eLife.05116.008Figure 3.Pairwise DNA content analyses in AD cortical nuclei vs AD cerebellum.(**A**) Pairwise analysis of overlaid DNA content histograms (CTX = solid red, CBL = black dashed lines) in the same AD individual (each graph represents a unique AD individual). (**B**) Pairwise analysis of overlaid DNA content histograms (CTX = solid blue, CBL = black dashed lines) in the same ND individual.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.008](10.7554/eLife.05116.008)

Neurons produce DNA content increases {#s2-2}
-------------------------------------

In the non-diseased cortex, neurons were identified as the predominant cell type contributing to increased DCV ([@bib76]). To determine whether neurons were also responsible for increased DCV in sporadic AD, nuclei were immunolabeled for the neuronal nuclear antigen, NeuN, and flow cytometry was used to analyze DCV in NeuN-positive and NeuN-negative nuclei ([Figure 4A--C](#fig4){ref-type="fig"}). NeuN-positive AD cortical neurons showed right hand DNA content shifts ([Figure 4D](#fig4){ref-type="fig"}) and increased DCV, displaying ∼9% gain over that observed in NeuN-negative nuclei ([Figure 4E](#fig4){ref-type="fig"}). A comparison of NeuN-positive nuclei in paired samples from the same brain also showed significantly increased DNA content in cortical neurons over cerebellar neurons ([Figure 4F](#fig4){ref-type="fig"}). These distinctions do not rule out AD-specific effects on DCV from non-neuronal cells, but do implicate neurons as the major cellular locus for increased DCV.10.7554/eLife.05116.009Figure 4.DNA content increases observed in AD cortical nuclei are attributable to neurons.(**A**--**C**) The gating procedure used for NeuN-positive flow cytometry analysis. (**A**) DNA content peak for identified nuclei. (**B**) A sample of unlabeled neuronal nuclei that display no NeuN-positive signal. (**C**) Selection for NeuN-positive nuclei for downstream analysis. (**D**) DNA content histograms of four AD samples displaying NeuN-positive nuclei (solid purple) vs NeuN-negative nuclei (black dashed line). NeuN-positive populations display distinct cortical histograms with prominent right-shifted peaks (arrows). (**E**) Comparison of DNA index (DI) increases from NeuN-positive nuclei (solid purple) vs NeuN-negative nuclei (black dashes) from AD CTX samples. NeuN-positive nuclei (DI = 1.10) showed an average gain of 9% over NeuN-negative nuclei (DI = 1.01), \*\*p = 0.0011. (**F**) Comparison of DNA content in NeuN-positive nuclei from AD CTX (DI = 1.10) (red) vs AD CBL (DI = 0.94) (pink) from the same individual; CTX nuclei displayed a 15.6% gain over CBL nuclei, \*p = 0.0335. Statistics are paired two-tailed *t*-test. Bars indicate ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.009](10.7554/eLife.05116.009)

*APP* copy number variably increases in small cell cohorts {#s2-3}
----------------------------------------------------------

The DNA content increases in sporadic AD neurons raised the question of what genomic loci may be specifically increased in AD. The most highly validated gene associated with AD is *APP,* wherein constitutive gains have previously been linked to AD through familial AD and DS ([@bib56]; [@bib63]; [@bib38]; [@bib46]). However, prior large-scale analyses in peripheral, non-neural tissues from sporadic AD cases have not reported *APP* copy number changes ([@bib3]; [@bib32]). The normal existence of genomic mosaicism might produce 'hot-spots' of cells with increased *APP* copy number, and we therefore interrogated small cohorts of brain nuclei from paired cortex and cerebellum. Three of six AD samples displayed significant increases in *APP* copy number (3.9--6.3 copies compared to reference genes) over paired cerebellar samples ([Figure 5A](#fig5){ref-type="fig"} (AD-1, AD-3, AD-6)). Similar *APP* amplification was not detected in non-diseased brains ([Figure 5B](#fig5){ref-type="fig"}), and DS controls along with reference gene assessments demonstrated expected results ([Figure 5---figure supplement 1A,B](#fig5s1){ref-type="fig"}). Notably, AD samples displayed substantial variability in *APP* copies ([Figure 5C](#fig5){ref-type="fig"}), revealing inherent limitations in precisely quantifying copy numbers in small, genomically mosaic cell populations and highlighting the necessity for single-cell analyses.10.7554/eLife.05116.010Figure 5.Mosaic amplification of the *APP* locus in small cohorts of AD cortical neurons unrelated to trisomy 21.(**A**) Comparison of relative copy number of *APP* in CBL and CTX fractions from six AD brains. *APP* locus-specific amplification was determined relative to reference gene *SEMA4A*; paired CBL nuclei were used as a calibrator sample for each brain, normalized to 2.00 for a diploid cell. Differences in ΔΔCt ± SEM of *APP* in the cortex vs cerebellum were assessed in each individual using an unpaired, two-tailed t-test (\*\*\*\*p = 0.0001, \*p = 0.0165, \*p = 0.0489) (**B**) Comparison of relative copy number of *APP* in CBL and CTX fractions from 4 non-diseased brains. (**C**) Average relative copy number in non-diseased vs AD brains. Control genes and DS individuals were also examined ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). (**D**--**J**) FISH strategy of chromosome 21 counting through simultaneous labeling using chr 21 q arm 'whole' chromosome paint (WCP, green) and chr 21 regional FISH probe for 21q22.13-q22.2 (red) (see [Figure 5---source data 1](#SD2-data){ref-type="supplementary-material"} for raw counts). (**D** and **E**) The ability to detect aneuploidy was validated using interphase nuclei from a human trisomy 21 brain, where three regional spots (red, encompassing the *APP* gene) were seen, despite WCP spatial variation (see also [@bib61]). (**F**--**I**) Chromosome 21 aneusomy was examined in prefrontal cortical nuclei. Examples of chr 21 (**F**) monosomy, (**G**) disomy, (**H**) trisomy, and (**I**) tetrasomy (please note tetrasomy is not an example of aneuploidy). (**J**) Quantification of individual FISH signals showed no significant differences in monosomy, disomy, trisomy, or tetrasomy. 5 control brains and 9 AD brains were used. At least 450 nuclei were quantified per brain sample. Scale bar = 10 um. 4974 total nuclei examined.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.010](10.7554/eLife.05116.010)10.7554/eLife.05116.011Figure 5---source data 1.Raw dual point-paint probe FISH counts.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.011](10.7554/eLife.05116.011)10.7554/eLife.05116.012Figure 5---figure supplement 1.Controls for small population qPCR.(**A**) Reference genes validated in small population qPCR via examination of *APP* exon 14 in Down Syndrome (DS) nuclei as a positive control. (**B**) Representative males (AD-1 and AD-6) displayed reduced copy number of PCDH11X, a gene located on the X chromosome, while a representative female demonstrates two copies of PCDH11X and CCL18, a second single copy control gene.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.012](10.7554/eLife.05116.012)

*APP* copy number increases in AD are not due to trisomy 21 {#s2-4}
-----------------------------------------------------------

*APP* gene dosage in familial AD and DS has driven hypotheses connecting AD pathogenesis with increased incidence of trisomy 21 ([@bib35]; [@bib55]; [@bib24]). We therefore examined AD cortical nuclei using a highly liberal protocol for calling aneusomies whereby borderline FISH profiles suggestive of aneusomy were always included in quantitative assessments, in an effort to detect possible differences between AD and control brains. Importantly, all analyses were conducted blind to the identity of samples, an approach made possible by interrogating purified nuclei rather than cells or tissues that themselves show identifying increases of plaques and tangles in AD. Nuclei were double-labeled with a commercially available chromosome 21 q-arm 'whole chromosome paint' (WCP) and a regional 'point' probe for 21q22.13-q22.2 (220 Kb) ([Figure 5D--I](#fig5){ref-type="fig"}). The ability of this technique to detect aneuploidy was validated using interphase nuclei from a human trisomy 21 brain ([@bib70]) revealing three nuclear signals ([Figure 5D,E](#fig5){ref-type="fig"}) (see also ([@bib61])). Three separate, blinded observers counted each sample. Despite using liberal counting criteria, no statistically significant changes in chromosome 21 aneuploidy rates, including trisomies, between AD (N = 4974 nuclei, N = 9 brains) and non-diseased brains (N = 2576 nuclei, N = 5 brains) were observed ([Figure 5J](#fig5){ref-type="fig"}). Comparably high levels of aneuploidy have been reported for chromosome 21 displaying no difference between AD and non-diseased hippocampal cells ([@bib73]). Thus, results from dual probe FISH analyses do not support increased trisomy 21 in AD but are consistent with alternative CNV mechanisms that could produce *APP* copy number values exceeding 3, as was observed in 75-genome qPCR analyses ([Figure 5](#fig5){ref-type="fig"}).

*APP* copy number is increased and enriched in single AD neurons {#s2-5}
----------------------------------------------------------------

Mosaic single-cell increases in *APP* copy number could explain variations observed in small cohort qPCR data. To assess *APP* copy number in single neurons, an optimized microfluidic protocol to assess genomic copy number via qPCR using a Biomark HD 48.48 Dynamic Array integrated fluidic circuit (IFC) (Fluidigm, South San Francisco) was adapted from gene expression protocols. Nuclei were isolated and interrogated at two reference genes (see Materials and methods) and two *APP* exons that flanked the majority of the coding sequence at the 5′ and 3′ ends of *APP* (exons 3 and 14). Samples were run in triplicate and assays in sextuplicate, which generated high numbers of replicate data points allowing for improved copy number resolution to an extent not possible by conventional qPCR ([@bib74]; [@bib78]). A total of 154 neuronal nuclei were individually examined from three AD and three non-diseased brains, within which nuclei from the cerebellum and prefrontal cortex were separately analyzed. In single AD cortical nuclei, significant increases in *APP* copy number, ranging up to 12 copies in a single nucleus ([Figure 6A,B](#fig6){ref-type="fig"}), were observed with a high concordance rate between exons ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). AD cortical nuclei displayed increased average copy numbers (∼3.8--4 copies) over control samples (∼1.7--2.2 copies) ([Figure 6A,B](#fig6){ref-type="fig"}), with increased frequencies of high copy number nuclei (six or more copies) ([Figures 6C and 5E](#fig5 fig6){ref-type="fig"}, red lines) primarily occurring in prefrontal cortex samples ([Figure 6C--F](#fig6){ref-type="fig"}). The AD cortex showed an approximately fourfold increase over the non-diseased cortex of nuclei with greater than 2 *APP* copies (55--66% vs 12--15%) ([Figure 6G,I](#fig6){ref-type="fig"}). In addition, nuclei with fewer than 2 *APP* copies were also identified. In neuronal nuclei with greater than two copies ([Figure 6G,I](#fig6){ref-type="fig"}, gold bars), AD cortical nuclei showed statistically significant increases (∼5 copies for both exons) over the other samples (∼3 copies for both exons) ([Figure 6H,J](#fig6){ref-type="fig"}). These data identify mosaic, neuroanatomically enriched and disease-associated increases in *APP* copy number in single, sporadic AD neurons.10.7554/eLife.05116.013Figure 6.Mosaic *APP* locus amplification in single neurons from AD brains.(**A**) Single nuclei relative copy numbers for exon 3 of *APP* from non-diseased (ND) CBL, ND CTX, AD CBL, and AD CTX; each black diamond represents one neuron. For each group, the mean is displayed in red and bars represent 95% confidence intervals. AD CTX showed a mean *APP* copy number of 3.80; this is significantly higher than AD CBL (2.23), ND CTX (1.60), and ND CBL (2.28). \*p = 0.0147, \*\*p = 0.0015, \*\*p \< 0.0012, ANOVA p \< 0.0001 (see [Figure 6---source data 1](#SD3-data){ref-type="supplementary-material"} for raw numbers and statistics). (**B**) Single nuclei relative copy numbers for exon 14 of *APP*, similar to (**A**). The two exons showed a high concordance ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) where the AD CTX showed a mean *APP* copy number of 3.40 while the AD CBL (2.34), ND CTX (1.44), and ND CBL (1.92) remained closer to 2 copies. \*p = 0.0163, \*\*p = 0.0016, \*\*\*\*p \< 0.0001, ANOVA p \< 0.0001. (**C**--**F**) Distribution of copy number calls for exon 3 (**C** and **D**) and exon 14 (**E** and **F**) binned by relative copy number. The AD CTX for both exons displayed unique distributions, with more nuclei falling into the high copy number bins. (**G** and **I**) Distribution of nuclei with copy numbers less than, equal to, and greater than two copies. (**H** and **J**) Average copy number increases in nuclei binned with greater than two copies (gold columns in **G**) (AD CTX: Exon 3 = 5.01, Exon 14 = 4.96, \*p = 0.0361). All statistics represent an ANOVA with a Tukey\'s multiple comparison test. Bars indicate ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.013](10.7554/eLife.05116.013)10.7554/eLife.05116.014Figure 6---source data 1.Single Cell qPCR Data and Statistics.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.014](10.7554/eLife.05116.014)10.7554/eLife.05116.015Figure 6---figure supplement 1.Concordance of *APP* exon 3 and 14 from single cell qPCR.(**A**) Relative copy numbers (RCN) for *APP* exon 3 and *APP* exon 14 displaying concordance between exons. 100 of 115 nuclei examined for both exons display copy numbers within one copy number call. 10 of the 15 remaining nuclei, while more than one copy number apart, were both called as gains. Bars represent RCN Min and RCN Max. (**B**) Scatter plot of average relative copy numbers. The data remain consistent with those displayed for individual exons ([Figure 6A,B](#fig6){ref-type="fig"}). Statistics represent an ANOVA with a Tukey\'s multiple comparison test. \*\*p \< 0.01, \*\*\*p \< 0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.015](10.7554/eLife.05116.015)

*APP* amplified loci can be visualized by PNA-FISH {#s2-6}
--------------------------------------------------

The identification of high *APP* copy number nuclei by single-cell qPCR suggested the possibility that amplified loci could produce detectable FISH signals. In chromosome 21 non-quantitative regional point probe FISH experiments, we occasionally observed variable puncta sizes ([Figure 5H,I](#fig5){ref-type="fig"}) ([@bib61]) that were initially dismissed as technical hybridization variability but which might potentially indicate sub-chromosomal variation of loci containing target sequences. However, conventional point-probe FISH analysis, while useful for assessments of aneusomy or rearrangements, cannot quantitatively evaluate copy number changes occurring as contiguous copies in close proximity to one another. Moreover, other conventional techniques for identifying copy number in single cells, such as single cell sequencing, rely heavily on genome amplification, which may introduce bias or mask CNVs. We therefore developed a detection assay based upon PNA chemistry. PNA probes hybridize with single base discrimination and have been used to quantify short repeat sequences such as those found on telomeres ([@bib8]; [@bib42]). This raised the possibility that amplified copies of *APP* could be identified using multiple PNA probes simultaneously hybridized to unique gene sequences, provided that amplification occurred in a physically constrained locus rather than being dispersed throughout the genome.

Nine PNA probes of 12--18 residues, each conjugated to a single Alexa-488 fluor, were designed against multiple sites of the same *APP* exons examined by single-cell qPCR, and validated both in silico and by blotting for specificity and linear quantitative behaviors ([Figure 7A](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1A--C](#fig7s1){ref-type="fig"}). Relative probe sequence locations were also designed to avoid fluorochrome proximity quenching. Single PNA probes did not produce a detectable signal in any samples using standard fluorescence microscopy used for aneusomy FISH ([@bib60], [@bib61]), contrasting with clearly detectable telomeric signals, which led to evaluation of more sensitive microscopic techniques including confocal, deconvolution ([@bib76]), and ultimately super resolution structured illumination microscopy (N-SIM, Nikon) ([@bib30]), which all failed to detect possible signals in AD nuclei. However, hybridization of increasing numbers of distinct PNA probes combined with N-SIM visualization resulted in the empirical determination of a threshold that identified one, and rarely two, punctate signals that were much more frequent in AD nuclei ([Figure 7B](#fig7){ref-type="fig"}), and with a frequency consistent with single-cell qPCR data ([Figure 6](#fig6){ref-type="fig"}). AD neuronal nuclei showed single purely green puncta ([Figure 7B](#fig7){ref-type="fig"}, \#1 arrow, [Video 1--6](#video1 video2 video3 video4 video5 video6){ref-type="other"}) and rarer two puncta signals ([Figure 7B](#fig7){ref-type="fig"}, \#3 arrow, [Video 6](#video6){ref-type="other"}), all of which could be differentiated from lipofuscin puncta that fluoresced in all channels ([Figure 7B](#fig7){ref-type="fig"}, \#2 arrow, [Video 5](#video5){ref-type="other"}). Internal positive control signals identified telomeres ([Figure 7](#fig7){ref-type="fig"}, red fluorescent puncta). Use of 3D-SIM enabled acquisition and analysis of super resolution projections of individual green puncta ([Figure 7B](#fig7){ref-type="fig"}) revealing a range of morphologies and intensities ([Figure 7B,D](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1D,E](#fig7s1){ref-type="fig"}) consistent with varied *APP* copy number and possibly distinct, intrachromosomal genomic organization. This threshold detection using multiple PNA probes targeting *APP* visualized green puncta in 56% of AD neuronal nuclei compared to 22% in non-diseased and 14% in DS ([Figure 7C](#fig7){ref-type="fig"}). There was no evidence of single-copy detection in any sample, contrasting with standard FISH data ([Figure 5D--I](#fig5){ref-type="fig"}), despite always showing telomeric signals. Compared to single-cell qPCR data, which reports both endogenous alleles in addition to amplification, copy numbers at a *single* locus below ∼2 were not visualized with PNA-FISH, allowing focused analyses on positive profiles resulting in fluorescence intensity plots ( [Figure 7D](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}) that were highly reminiscent of *APP* copy number plots produced by single-cell qPCR ([Figure 6](#fig6){ref-type="fig"}).10.7554/eLife.05116.016Figure 7.Visualization of *APP* copy number increases in neuronal nuclei from AD brain samples.(**A**) Peptide nucleic acid probes (PNA) were developed against nine separate sites on *APP* (4 sites within exon 3 and 5 sites within exon 14). Each PNA probe consists of a peptide backbone conjugated to a single fluorophore, with separately conjugated nucleotides, substantially increasing specificity ([@bib42]). Single copies of *APP* are not detectable because of fluorophore detection limits. Detection of increased copy number by PNA probes can be visualized as copies of *APP* increase ([Figure 7---figure supplement 1B,C](#fig7s1){ref-type="fig"}). Positive internal controls using PNA probes directed against telomere sequences were simultaneously hybridized. (**B**) Visualization of copy number increases in neuronal nuclei. Green puncta (arrow 1, insets) indicate visualized *APP* increases. Telomere labeling (red puncta) was present in all nuclei, demonstrating probe accessibility and template fidelity. Lipofuscin (arrow 2, orange puncta) was detected in nuclei, visualized by extensive fluorescence signal in all channels, but was eliminated from quantifications. Limited nuclei displayed two green puncta (arrow 3). V1-6 Refers to the supplemental videos where 3-D projections can be visualized. (**C**) Graphic representation of non-diseased (blue) and DS (grey) brains displayed limited numbers of threshold-detected increases in *APP* ([Figure 7---source data 1](#SD4-data){ref-type="supplementary-material"}). AD (red) brains displayed significant and consistent threshold-detected increases in *APP*. (**D**) Individual threshold-detected *APP* increases were quantified and plotted on a relative intensity scale (blue diamonds: non-diseased, red diamonds: AD). Dotted line represents the threshold below which *APP* copy number was undetectable, only limited puncta were identified in non-diseased nuclei. Bars indicate ± SEM, \*p \< 0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.016](10.7554/eLife.05116.016)10.7554/eLife.05116.017Figure 7---source data 1.Data and statistics for PNA-FISH counts.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.017](10.7554/eLife.05116.017)10.7554/eLife.05116.018Figure 7---figure supplement 1.PNA FISH controls.(**A**) *PNA* probe specificity was verified via dot blots of *APP* sequence followed by PNA probe hybridization and immunoblotting against the Alexa-488 fluorophor. Probes designed against exon 3 exhibited specific binding to the 5′ region of *APP*, and probes designed against exon 14 exhibited specific binding to the 3′ region of *APP*, while probes did not display significant binding to non-specific sequences. (**B**) Plasmids containing all 9 *APP* PNA binding sites were blotted at 1× (1.8 µg), 2× (3.6 µg), and 3× (5.4 µg) DNA concentration, and PNA probes were hybridized and an empty plasmid at 1.8 μg was used for a negative control in lane 1. Fluorescent output demonstrated a linear increase with increasing DNA concentration. (**C**) 10 μg of plasmids containing 0, 3, 6, and 9 copies of the *APP* PNA binding sites was blotted onto membrane and probes were hybridized. Fluorescent output showed an expected linear increase with the number of PNA probe binding sites. (**D**) Quantification of the variable *APP* signal increases observed across four brains. (**E**) Representative *APP* signals visualized and verified using super-resolution 3D projections displayed a range of variable intensities.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.018](10.7554/eLife.05116.018)Video 1.PNA-Fish analysis of *APP* in nuclei from non-diseased cortical neurons.Video of 3-D projection from [Figure 7B](#fig7){ref-type="fig"}, V1. Green puncta indicating *APP* increases were infrequently visualized in non-diseased brains. Red puncta indicate telomere labeling with separate telomere-specific PNA probes and were visualized as a positive control for PNA hybridization.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.019](10.7554/eLife.05116.019)10.7554/eLife.05116.019Video 2.PNA-Fish analysis of *APP* in nuclei from non-diseased cortical neurons with lipofuscin.Video of 3-D projection from [Figure 7B](#fig7){ref-type="fig"}, V2. Green puncta indicating *APP* increases were infrequently visualized in non-diseased brains. Lipofuscin (orange puncta), visualized by extensive fluorescence signal in all channels, was detected in some nuclei, but was excluded from analysis. Red puncta indicate telomere labeling with separate telomere-specific PNA probes and were visualized as a positive control for PNA hybridization.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.020](10.7554/eLife.05116.020)10.7554/eLife.05116.020Video 3.PNA-Fish analysis of *APP* in nuclei from non-diseased cortical neurons.Video of 3-D projection from [Figure 7B](#fig7){ref-type="fig"}, V3. Green puncta indicating *APP* increases were infrequently visualized in non-diseased brains. Red puncta indicate telomere labeling with separate telomere-specific PNA probes and were visualized as a positive control for PNA hybridization.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.021](10.7554/eLife.05116.021)10.7554/eLife.05116.021Video 4.PNA-Fish analysis of *APP* in nuclei from AD cortical neurons.Video of 3-D projection from [Figure 7B](#fig7){ref-type="fig"}, V4. Green puncta indicate visualized *APP* increases. Red puncta indicate telomere labeling with separate telomere-specific PNA probes and were visualized as a positive control for PNA hybridization.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.022](10.7554/eLife.05116.022)10.7554/eLife.05116.022Video 5.PNA-Fish analysis of *APP* in nuclei from AD cortical neurons with lipofuscin.Video of 3-D projection from [Figure 7B](#fig7){ref-type="fig"}, V5. Green puncta indicate visualized *APP* increases. Lipofuscin (orange puncta), visualized by extensive fluorescence signal in all channels, was detected in some nuclei, but was excluded from analysis. Red puncta indicate telomere labeling with separate telomere-specific PNA probes and were visualized as a positive control for PNA hybridization.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.023](10.7554/eLife.05116.023)10.7554/eLife.05116.023Video 6.PNA-Fish analysis of *APP* in nuclei from AD cortical neurons.Video of 3-D projection from [Figure 7B](#fig7){ref-type="fig"}, V6. Green puncta indicate visualized *APP* increases. Limited nuclei in AD displayed two green puncta. Red puncta indicate telomere labeling with separate telomere-specific PNA probes and were visualized as a positive control for PNA hybridization.**DOI:** [http://dx.doi.org/10.7554/eLife.05116.024](10.7554/eLife.05116.024)10.7554/eLife.05116.024

Discussion {#s3}
==========

Our results support a mechanism for the development of sporadic AD whereby the validated familial pathogenic *APP* gene is mosaically amplified in neurons. Mosaicism was documented based on multiple independent criteria: increased DCV in 90% of examined AD brains, varied and increased *APP* copy number in small cohorts, increased *APP* CNVs in single neurons identified by single-cell qPCR, and *APP* copy number increases in single nuclei visualized by PNA-FISH. These data are consistent with our inability to substantiate increases in trisomy 21 in cells of the sporadic AD brain. The concomitant increase in DCV suggests effects on other loci that are also altered in AD, the most obvious of which would be copy gains, but which could also involve losses based upon the presence of increased DCV range observed in AD; such loci might contribute to the progeric presentation of sporadic AD and possibly familial forms of AD that still require decades for disease to manifest. Our working hypothesis ties the currently accepted pathogenicity of *APP* gene dosage, established by familial AD and DS, to sporadic AD through a mechanism of somatic, mosaically increased *APP* copy number in some neurons. Our data do not exclude the possibility that the changes observed are a downstream effect of causative factors in the disease. However, if mosaic genomic changes are downstream of disease onset, *APP* copy number changes would likely play a significant role in disease progression.

Advances in single-cell genomic sequencing had initially suggested its use for identifying *APP* CNVs in single AD neurons. However, existent technology is limited to published sequence resolution between ∼2-5 Mb and ∼0.025X genome coverage ([@bib21]; [@bib28]; [@bib45]; [@bib11]). Considering the \<0.3 Mb size of the *APP* locus, single cell sequencing would be incapable of identifying all but the rarest *APP* CNVs observed here. In addition, whole genome single cell sequencing is limited by throughput, demonstrated by the low number of neurons reported in this field, and is complicated further by variable results (Cai et al. N = 82 (QC neurons), Evrony et al. N = 6, Gole et al. N = 6, McConnell et al. N = 110). Notably, DNA losses predominated in both [@bib11] and [@bib45] however, [@bib28] observed that two thirds of somatic CNVs were gains, consistent with increases in DNA content reported previously, and all three studies support a *range* of DCV amongst neurons, although none of these prior studies assessed AD neurons. While future advances will improve sequence resolution, throughput, and amplification fidelity in single cells, the distinct single cell strategy employed here allowed copy number assessment of a single targeted gene, *APP*, an approach which may be generalizable to other loci and diseases. Compared to the prior single-neuron reports, 320 single, neuronal nuclei were assessed here for *APP* CNVs wherein single cell qPCR data markedly resembled PNA-FISH data. Notably, these single cell techniques also possess limitations. For example, single cell qPCR requires normalization to single copy reference genes and control populations, which presents unique difficulties in assessing mosaic neuronal populations. For example, changes in copy number could reflect changes in both the reference and target gene, which might result in artifactual increases (or decreases) in a target gene. Similarly, assessment of copy number from an amplified template could also produce artifactual changes, and thus results require independent techniques for verification, especially since the original template is consumed in the single cell reaction and cannot be further assessed. The use of PNA-FISH does not require any amplification or normalization, and yet PNA-FISH and single-cell qPCR produced a highly similar distribution of APP copy number amplifications. The employed techniques were not capable of assessing intact neurons or their histological organization, which will require technological modifications. Similarly, assessments of genomic and expression data in a single neuron also await technological advancements. Finally, these techniques are currently capable of interrogating only parts of the entire APP locus; therefore, at this time the precise structure of APP CNVs and the mechanisms leading to their existence are unknown.

Our data have bearing on at least 3 AD hypotheses. First, the prevailing amyloid hypothesis in AD posits that Aβ deposition drives AD ([@bib31]). Increased incidences of amyloid senile plaques are observed in all forms of AD and appear to be directly linked to *APP* dosage in DS and familial AD. The mosaic increases in neuronal *APP* copy number reported here provide an explanation for the universal presence of Aβ senile plaques in sporadic forms---indeed, all forms---of AD despite an absence of constitutive copy number gain. The presence of rare neurons with *APP* amplifications in non-diseased brains also provides an explanation for the observed presence of senile plaques in otherwise normal, aged brains ([@bib25]; [@bib14]; [@bib44]), consistent with the ages of non-diseased brains examined here, which exceeded 75 years. Along with the occurrence and augmentation of DCV, *APP* amplification in AD is consistent with dysregulation of normally occurring processes in the etiology of AD pathogenesis. A second hypothesis proposes increased *APP* dosage through trisomy 21 based largely upon the neuropathology of DS ([@bib35]; [@bib55]; [@bib24]). However, dual chromosome point-paint FISH for chromosome 21 using liberal calling criteria on ∼5000 AD brain cells (N = 14 brains) showed no relationship between total mosaic aneusomies and AD. Moreover, the lack of observed increases of trisomy 21 in sporadic AD are consistent with prior studies in both peripheral non-brain and intact brain tissues, which reported *APP* levels approximating 2N ([@bib54]; [@bib67]; [@bib72]; [@bib4]), and is further consistent with mosaic CNVs observed here. The purposeful use of liberal counting criteria resulted in generally higher percentages of aneusomies than reported previously ([@bib61]; [@bib36]), however the increases were observed in both AD and non-diseased samples without linkage to AD. Our results do not eliminate roles for mosaic aneuploidy in AD, but do not support trisomy 21 as a specific mechanism for increasing *APP* copy number in sporadic AD. A third hypothesis is that abnormal cell cycle reentry in post-mitotic neurons contributes to AD ([@bib80]; [@bib33]; [@bib41]; [@bib13]; [@bib47]; [@bib34]). Our DCV analyses detected maximum gains of ∼21% and average gains of ∼8.2% over lymphocytes, representing a fraction of the 100% increase expected in a 4N cell. The subgenomic increases observed here are also consistent with the reported absence of adult neurogenesis in the normal cerebral cortex ([@bib59]; [@bib5]), and could also be relevant to reports of nucleotide incorporation in adult cortical neurons ([@bib29]). Concepts involving changes in DNA synthesis in AD without cell-cycle progression or neurogenesis could be rectified through subgenomic DNA synthesis in post-mitotic neurons that might involve DNA synthetic proteins reported in AD ([@bib12], [@bib13]).

The observed genomic alterations in AD could occur through both developmental as well as aging processes as reported for at least one form of mosaicism, aneuploidies ([@bib9]) that have been linked to caspase-mediated cell death ([@bib51]) and could have relevance to developmental *APP* functions ([@bib49]). Perhaps tellingly, these developmental cell death processes also involve DNA fragmentation and double strand breaks ([@bib6]; [@bib68]; [@bib7]) that have recently been reported in neurons exposed to physiological and AD stimuli ([@bib69]). It is possible that somatic mosaicism may arise through dysfunction of normally operative DNA repair mechanisms that produce DCV in the normal brain, with augmentation in the diseased brain. We speculate that increased DCV and *APP* CNVs observed in AD may in part reflect neurons that have delayed or averted cell death, wherein somatic genomic changes could provide a survival advantage at a cost of altered neurophysiological functions.

The DNA content changes observed here showed not only disease relationships but also varied with brain region and cell type. It is important to note that the interrogated neurons are likely terminal in their fate: they will not divide further, contrasting with lymphocytes that, perhaps surprisingly, showed the least amount of DCV despite being a proliferating population. Unlike neurons, proliferating lymphocytes may be similar to stem and progenitor populations that can maintain germline genomes to promote population expansion. By contrast, neurons are by definition post-mitotic, and therefore not subject to this possible requirement. We think it likely that many dividing cells that deviate significantly from the germline genome---and thus would be incapable of further division---are eliminated by cell death and would be removed from the population interrogated for DNA content. Support for this view includes reports on aneuploidies in neuroprogenitor cells, whereby the most extremely aneuploid forms appear to be eliminated by caspase-mediated cell death ([@bib6], [@bib7]; [@bib50]; [@bib51]). DNA content changes may therefore be contextual, enabling diverse functions in different cell types. The large differences observed even between brain regions and amongst neuronal nuclei would suggest the existence of distinct neuronal functions produced by DCV, and possibly specific processes or stimuli that can genomically alter neurons.

Diverse stimuli previously implicated as AD risk factors including age and trauma ([@bib65]; [@bib53]), might share common endpoints via influences on genomic mosaicism. The consequences of somatic *APP* amplification in AD may support functionality of other somatically altered genomic loci observed in single neurons that could contribute to the progeric presentation of AD as well as aspects of the disease itself. We further hypothesize that other sporadic or idiopathic brain diseases could arise through altered genomic mosaicism that includes somatic variations at both known and unknown pathogenic loci.

Materials and methods {#s4}
=====================

Human tissue samples {#s4-1}
--------------------

All human tissue protocols were approved by the Scripps Office for the Protection of Research Subjects (SOPRS) at The Scripps Research Institute (TSRI) and conform to National Institutes of Health guidelines. Fresh-frozen brain tissue was provided by the NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland, the University of California Alzheimer\'s Disease Research Center (UCI-ADRC), and the Institute for Memory Impairments and Neurological Disorders, the Johns Hopkins School of Medicine Alzheimer\'s Disease Research Center, and Dr Edward Koo at the University of California, San Diego. Lymphocytes from human peripheral blood were obtained from healthy donors at TSRI\'s Normal Blood Donor Services. Detailed information about the samples used can be found in the table below ([Table 1](#tbl1){ref-type="table"}).10.7554/eLife.05116.025Table 1.Human samples used in each experiment**DOI:** [http://dx.doi.org/10.7554/eLife.05116.025](10.7554/eLife.05116.025)SexAgePaper codeSampleExperimentsPost mortem intervalBraak scoreAlzheimer\'s disease prefrontal cortex, N = 32F811521D23VIF831562D6UF74**AD-131866**DTUUF79**AD-51868**DSTUUF82**AD-101875**DSTUUF831893D9UF871899D5VIF62**AD-91912**DSTUUF80**AD-81913**DTUUF54**AD-41916**DTBUUF72**AD-21921**DTBUUF772400D3.7VF80**AD-11**2500DP2.3VIF10150341D19VF9161788D11VF9862405D11VF8962439D11VF7762509D18VIM88**AD-1102**DSBP3IVM90268D91VM83736D27UM821211D18UM79**AD-151252**D9UM921748D5.5VM85**AD-121861**DTUUM85**AD-141870**DTUUM82**AD-32401**DSBP3VIM84**AD-62499**DS3.4VIM63**AD-74199**DP3VIM8013173D22IVM9430022D20VM9160987D22.5V**Mean82.1**Alzheimer\'s disease cerebellum, N = 15F74**AD-131866**DUUF79**AD-51868**DSUUF82**AD-101875**DSUUF80**AD-81913**DUUF62**AD-91912**DSUUF54**AD-41916**DBUUF72**AD-21921**DBUUM88**AD-1102**DSB3IVM79**AD-151252**D9UM701625D1UM85**AD-121861**DUUM85**AD-141870**DUUM82**AD-32401**DSB3VIM84**AD-62499**DS3.4VIM63**AD-74199**D3VI**Mean75.9**Non-diseased prefrontal cortex, N = 40F74**ND-21901**DSBP2.3IIF74**ND-8299**D2.8IIF84**ND-3703**S5.8IIIF53**ND-111379**D15IIIF73713[\*](#tblfn1){ref-type="table-fn"}TUUF9560831D9IIF511568P22UF171230P16UF87**ND-101502**D5IIF8060728D13IIM79**ND-9827**[\*](#tblfn1){ref-type="table-fn"}DTUUM96**ND-11102**DSB3.4IIM83**ND-52501**DB1.7IIM95**ND-41301**DS3.5IM87**1471**[\*](#tblfn1){ref-type="table-fn"}TUUF71**1571**[\*](#tblfn1){ref-type="table-fn"}TUUM53**1344**[\*](#tblfn1){ref-type="table-fn"}DTUUF93318D2.3VIF92955D20.5IIIF564238D12M704534D28F9111488D16IIF7913188D12.5F9013204D9.5IIF10360329D5IIIF8560428D8.5IIIF9960524D15IIF9562043D20.5M71389M15F83719M17IIIM69946M12M872039M6.3IIIF864546M22M9160772M16IIF8061218M5.5M8761334M8IIM88PDC2MUM80PDC5MUM75PDC8MU**Mean79.54**Non-diseased cebellum, N = 15F74**ND-21901**DSB2.3IIF74**ND-8299**D2.8IIF84**ND-3703**S5.8IIIF771569D8IIIF83719DUUF53**1379**D15IIIF71**1571**DTUUF87**ND-10**1502D5IIM53**1344**DTUUM96**ND-11102**DSB3.4IIM83**ND-52501**DB1.7IIM95**ND-41301**DS3.5IM79**ND-9827**DUUM87**1471**DUUF864546M22U**Mean78.8**DS/AD, N = 3F51**DS-1**M1864B19UF47**DS-2**M3233S24UF44**DS-3**1258S13U**Mean47.3**LYM, N = 21F405162DN/AN/AF403963DN/AN/AF634984DN/AN/AF604519DN/AN/AM55Lym 1DN/AN/AM354651DN/AN/A29DN/AN/A187DN/AN/A4781DN/AN/A4801DN/AN/A4903DN/AN/AM285259DN/AN/AM5683MF52**1344**MF564603MM544609MM58Lym 2MF51Lym 3MM52Lym 4M**Mean50.0**M[^4][^5]

Flow cytometry (FCM) and fluorescence-activated cell sorting (FACS) {#s4-2}
-------------------------------------------------------------------

Human brain nuclei were isolated and prepared for FCM and FACS as previously described ([@bib75], [@bib76]). Isolated nuclei were fixed with 2% paraformaldehyde (or 70% ethanol for microfluidic qPCR), labeled with mouse anti-NeuN antibody (1:100) (Millipore, Germany) and Alexa Fluor 488 goat anti-mouse IgG secondary (1:250) (Life Technologies, Carlsbad, CA), and counterstained with propidium iodide (50 μg/ml) (Sigma, St. Louis, MO) in solution containing 50 μg/ml RNase A (Qiagen, Valencia, CA) and chicken erythrocyte nuclei (CEN) (Biosure, Grass Valley, CA). Electronically gated diploid neuronal nuclei, determined by PI fluorescence and immunolabeling, were analyzed and sorted either in bulk for standard qPCR and PNA-FISH or singly in 96-well plates for microfluidics-based qPCR. FCM and FACS were performed at the TSRI Flow Cytometry Core using a Becton Dickinson (BD Biosciences, San Jose, CA) LSRII and FACS-Aria II, respectively. *Post hoc* DNA content analyses were performed using FlowJo software (TreeStar Inc., Ashland, OR).

DNA content assessment by whole genome amplification {#s4-3}
----------------------------------------------------

For validation of DNA content analyses, nuclei were sorted by FACS in populations of 1000, 500, and 100 into 96-well plates according to relative DNA content ([Figure 2A](#fig2){ref-type="fig"}). Nuclei were denatured by multiple freeze--thaw cycles and potassium hydroxide, the solution was neutralized, and phi29 DNA polymerase (Illumina, San Diego, CA), dNTPs, SYBR green, and random hexamers (IDT, Coralville, IA) were added ([@bib28]). The MDA reaction was performed at 30°C and SYBR Green intensity was recorded every 2 min on a QuantStudio RT-PCR 12K Flex (Life Technologies, Carlsbad, CA). 12 replicates were run and averaged for each group.

Quantitative PCR primers {#s4-4}
------------------------

All qPCR was performed according to MIQE guidelines ([@bib10]). For standard qPCR, primers against the *APP* gene exon 14 and reference genes *SEMA4A*, *CCL18*, and *PCDH11X* were designed in house and optimized to an annealing temperature of 59°C using Primer3 software (University of Massachusetts Medical School) and synthesized by Valuegene (San Diego, CA) ([Table 2](#tbl2){ref-type="table"}). For microfluidics-based qPCR, TaqMan assays against *APP* exons 3 and 14 (178 kb apart) (designed from NCBI Reference Sequence: NG_007376.1), *SEMA4A* and *PCDH11X* were synthesized by Applied Biosystems (Life Technologies, Carlsbad, CA) or Integrated DNA Technologies (*APP* exon 3) (San Diego, CA) and optimized to an annealing temperature of 60°C. Primers were assessed in silico to determine specificity of the primer set for a single genomic region and for the presence of SNPs in the targeted genomic region which could decrease primer binding and amplification efficiency. The specificity of all qPCR assays was assessed by gel electrophoresis to confirm a single PCR product of the expected length and sequenced to confirm amplification of the expected product.10.7554/eLife.05116.026Table 2.Primers used for small population and single nuclei qPCR**DOI:** [http://dx.doi.org/10.7554/eLife.05116.026](10.7554/eLife.05116.026)GeneProteinLocusAssay typePrimer sequenceProbeProduct lengthEfficiency*APP*, Exon 14Amyloid precursor protein21q21.3SYBR GreenF-TGCACGTGAAAGCAGTTGAAG, R-AAAGATGGCATGAGAGCATCGN/A2140.973SEMA4ASemaphorin 4A1q22SYBR GreenF- ATGCCCAGGGTCAGATACTAT, R-TTCTCCGAGATCCTCTGTTTCN/A1770.997CCL18Chemokine (C--C motif) ligand 1817q11.2SYBR GreenF-TTCCTGACTCTCAAGGAAAGG, R-CTGGCACTTACATGACACCTGN/A2091.006PCDH11XProtocadherin 11 X-linkedXq21.3SYBR GreenF-TCTTTTGGTCAGTGTTGTGCG, R-CAACAAGTCGCCTATCAGGACN/A1880.993*APP*, Exon 14Amyloid precursor protein21q21.3TaqManCGGTCAAAGATGGCATGAGAGCATC[\*](#tblfn2){ref-type="table-fn"}, Assay Hs01255859_cnFAM-MGB911.040*APP*, Exon 3Amyloid precursor protein21q21.3TaqManF-GCACTTCTGGTCCCAAGCAT, R-CCAGTTCTGGATGGTCACTGROX-IB1400.992SEMA4ASemaphorin 4A1q22TaqManGTTCAAGGGTATGTGAGGTGAGATG[\*](#tblfn2){ref-type="table-fn"}, Assay Hs00329046_cn_VICVIC-MGB901.016[^6]

Standard curves were used to determine the amplification efficiency of all primer sets used for qPCR. For standard qPCR primers, curves were created by serially diluting purified pGEM-T Easy plasmid DNA (Promega, Madison, WI) containing a single copy of the gene of interest ([@bib52]); serial dilutions of genomic DNA were used for TaqMan primers ([@bib18]). DNA concentrations were converted to gene copy number by calculating the weight (in g/mol) of the DNA used for generating the standard curve. A linear regression of the curve comparing the log of the gene copy number vs the crossing threshold (Ct) of the primer set was determined from primer efficiency (E) = 10^−1/slope^ − 1 ([@bib52]). Only standard curves with R^2^ values of greater than 0.99 were used.

Standard qPCR on small neuronal populations {#s4-5}
-------------------------------------------

Genomic DNA from bulk-sorted nuclei (described above) was isolated using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) and quantified using Quant-iT PicoGreen (Life Technologies, Carlsbad, CA); genomic DNA was stored at −20°C before use. Standard qPCR reactions using SYBR Green (Promega, Madison, WI) fluorescence detection (ex: 494 nm; em: 529 nm) were performed in triplicate using 0.5 ng of sample gDNA per reaction. Reactions were run on a Rotor-Gene RG-3000 72-well thermocycler (Qiagen, Valencia, CA) using GoTaq qPCR master mix (Promega, Madison, WI) and the following parameters: denaturation (95°C for 5 min), amplification (95°C for 25 s, 59°C for 30 s and 72°C for 30 s), and quantification through 40 cycles; and a melting curve determination (55--99°C, 30 s on the first step, 5 s for each subsequent step). The crossing threshold (Ct) was determined for each primer set within the linear region of the amplification curve. Down Syndrome nuclei were used as a control.

Microfluidics-based qPCR on single neuronal nuclei {#s4-6}
--------------------------------------------------

Single neuronal nuclei from FACS were sorted directly into a 96-well plate containing QuickExtract DNA Extraction Solution (Epicentre, Illumina, San Diego, CA) according to the manufacturer's instructions. Multiple independent sorts were completed for each group and each individual. Prior to analysis on the Fluidigm Biomark HD (South San Francisco, CA), single neuron genomic DNA was pre-amplified as per Fluidigm protocols ([@bib22]; [@bib20]; [@bib58]; [@bib37]; [@bib79]; [@bib78]) on a Veriti thermocycler (Life Technologies, Carlsbad, CA) using locus-specific Taq-man primer sets (primer Table above) (20× initial concentration, 18 µM primer, 5 µM probe; combined and diluted to 0.2×) (95°C denaturation for 5 min; 18 amplification cycles of a 95°C denaturation for 15 s, followed by a 60°C annealing and extension step for 4 min; and a final extension step at 72°C for 7 min). Locus-specific pre-amplification was confirmed on a Roche LightCycler (Roche Applied Science, Indianapolis, IN) using one targeted primer set prior to analysis on the Biomark 48.48 Dynamic Array integrated fluidic circuit (IFC) (Fluidigm, South San Francisco, CA). Samples were diluted 1:5 and loaded into the 48.48 Dynamic Array IFC according to the manufacturer\'s protocol. DNA was loaded in triplicate and assays in sextuplicate for a total of 18 replicates per assay per nucleus. Samples were run across multiple arrays for quality control between runs ([Table 3](#tbl3){ref-type="table"}) and multiple individuals were run on each array. The thermocycling program was performed on the Biomark: 95°C for 10 min, then 55 cycles of 95°C denaturation, and 60°C annealing and extension. Fluorescent probes used for these assays were 5′-FAM or 5′-VIC with a 3′-minor groove binding (MGB) non-fluorescent quencher, or 5′-ROX with a 3′ Iowa Black quencher. Ct values were determined using Fluidigm\'s Real-Time PCR Analysis Software. Only nuclei with 10 or more replicates per assay were used for analysis.10.7554/eLife.05116.027Table 3.Quality control between 48.48 Dynamic Array runs**DOI:** [http://dx.doi.org/10.7554/eLife.05116.027](10.7554/eLife.05116.027)Cell 1Cell 2Cell 3Cell 4Cell 5Cell 6Cell 7Cell 8APP 14Run 121.3718.7718.0218.3417.1119.3320.1218.02Run 220.6018.7718.1418.4117.2519.5020.6018.26APP3Run 122.7920.3518.5319.11Run 221.9719.8418.6519.28SEMA4ARun 125.5424.2922.4424.2322.8125.7424.4624.67Run 225.2624.5323.9224.3923.0325.4224.1124.30

Quantitative PCR analysis {#s4-7}
-------------------------

For both qPCR strategies, relative copy number (RCN) for a diploid sample was calculated as RCN = 2 × (1 + E)^−ΔΔCt^ where E is primer efficiency (E = 10^−1/slope^ − 1) ([@bib74]; [@bib52]; [@bib18]; [@bib43]). Paired cerebellar samples were used as a calibrator to determine ΔΔCt values. For single cell RCN determinations, cerebellar ΔCt values for the paired cerebellum were averaged. RCNs were modeled for each copy number 1--6, assuming a system standard deviation of 0.25 and a 95% CI equal to the standard error of the mean multiplied by the critical t value for a two-tailed t-distribution (degrees of freedom = 68) with p = 0.05 ([@bib74]). 95% confidence interval (CI) was also determined for the RCN of each assay for each single nucleus giving RCN = 2 × (1 + E)^−ΔΔCt^ ± CI, and the upper and lower bounds were used to call copy numbers for *APP* exons 3 and 14 such that a CI that overlapped with the modeled RCN range was considered as belonging in that copy number bin (See [Table 4](#tbl4){ref-type="table"} for modeled upper and lower bounds). Copy number bins were 1--6 and \>6, as beyond 6 copies the CIs for the given degrees of freedom begin to overlap, allowing for assessments of significant increases in copy number but limiting the ability to distinguish between nuclei with, for example, 8 vs 9 copies. There was high concordance between the *APP* exons 3 and 14 demonstrating minimal amplification bias between the primer sets.10.7554/eLife.05116.028Table 4.Confidence Intervals for (CI) calling Copy Number (CN)**DOI:** [http://dx.doi.org/10.7554/eLife.05116.028](10.7554/eLife.05116.028)CNCIRCN, value1Lower0.92156Upper1.085122Lower1.84312Upper2.170233Lower2.76468Upper3.255354Lower3.68624Upper4.340475Lower4.60780Upper5.425596Lower5.52936Upper6.51070

Statistical analysis {#s4-8}
--------------------

For DNA content FCM, DNA indices (DIs) were determined by taking the ratio of the mean from the diploid (2N) peak from the brain sample to the mean of the lymphocyte control peak, both normalized to the mean of the CEN standard ([@bib15]; [@bib16]; [@bib76]). The percent change was calculated from DI values assuming a 2N diploid would have a DI of 1. p values for comparison of mean percent change, skew and coefficients of variation comparisons were determined by one-way ANOVA and Tukey\'s multiple comparison tests. Linear regression analysis was used to determine age-percent change correlation. For comparison of average percent change from NeuN-positive vs negative cortical nuclei, or NeuN-positive cortical and cerebellar nuclei, p values were determined by unpaired, two-tailed t-test. For standard qPCR analyses, differences in ΔΔCt ± SEM of *APP* in the cortex vs cerebellum were assessed in each individual using an unpaired, two-tailed t-test. For single cell qPCR, p values were determined by one-way ANOVA and Tukey\'s multiple comparison tests.

Fluorescent in situ hybridization {#s4-9}
---------------------------------

Isolated nuclei were stained with DAPI and hybridized using dual color FISH as described previously ([@bib60]; [@bib39]). FISH paints against the whole q arm of chromosome 21 and a point probe against a region on the q arm of 21 (21q22.13-q22.2) (Vysis. Downer\'s Grove, IL) were used. The mounted slides were examined on a Zeiss Axioskop microscope and Axiocam CCD camera (Carl Zeiss, Thornwood, NY). Approximately, 500 nuclei were blindly counted for each brain, by two independent observers, on 14 samples (5 non-diseased, 9 diseased). Total AD cortical nuclei were examined using a highly liberal protocol for calling aneusomies whereby borderline FISH profiles suggestive of aneusomy were always included in quantitative assessments. All analyses were conducted blind to the identity of samples by interrogating purified nuclei. The ability of this technique to detect aneuploidy was validated using interphase nuclei from a human trisomy 21 brain ([@bib70]) revealing three nuclear signals ([Figure 5D,E](#fig5){ref-type="fig"}).

PNA probe design and dot blot confirmation {#s4-10}
------------------------------------------

Peptide nucleic acid probes were custom designed in coordination with PNA Bio, Inc. Nucleic acid sequences were identified and analyzed in silico to ensure binding to only one specific genomic region on *APP*. Nine unique probes (4 on exon 3 and 5 on exon 14) were designed and conjugated to a single fluorophore of Alexa-488 ([Table 5](#tbl5){ref-type="table"}). Specificity of probes was confirmed using dot blot DNA detection paired with immunoblot via antibodies against the Alexa-488 fluorophore (AF-488) ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Increasing DNA concentration (1.8, 3.6 and 5.4 μg) of plasmids containing one copy of each exon (all nine PNA binding sites) was used to verify linear increases in AF-488 signal ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). For the APP copy number curve, DNA concentration remained consistent but plasmids containing 0, 3, 6, and 9 copies of all APP PNA binding sites were used. DNA was denatured in 0.1 M NaCl at 50°C and dot blotted onto a positively charged nylon membrane in distilled deionized water (DDW) and washed in 6× SSC. DNA was cross linked to the membrane, and PNA probes were hybridized to the membrane using conditions consistent with probe hybridization to nuclei on slides. Briefly, probes were prepared in 20 mM Tris, 60% formamide, and 0.1 μg/ml salmon sperm. Probes and membrane were heated 85°C for 5 min, and probes were added to the membrane and incubated at 85°C for 10 min, followed by room temperature overnight. Membrane was then washed twice at 60°C in 2× SSC + 0.1% Tween-20, and then in successive washes of 2× SSC, 1× SSC, and DDW. Probes were visualized on the membrane using a Typhoon fluorescence scanner from General Electric (Fairfield, CT). For quantification, color data were removed, image was inverted, brightness/contrast was adjusted evenly across the entire image, and average pixel intensity was acquired for a region of interest with a standardized area across sample comparisons.10.7554/eLife.05116.029Table 5.Peptide nucleic acid (PNA) probe sequences**DOI:** [http://dx.doi.org/10.7554/eLife.05116.029](10.7554/eLife.05116.029)GeneProteinLocusAssaySequenceAPP Exon 3Amyloid precursor protein21q21.3PNA FISHA488-GATGGGTCTTGCACTG, A488-CCCCGCTTGCACCAGTT, A488-GGTTGGCTTCTACCACA, A488-CAGTTCAGGGTAGACAPP Exon 14Amyloid precursor protein21q21.3PNA FISHA488-CTCCATTCACGG, A488-GTGGTTTTCGTTTCGGT, A488-ACTGATCCTTGGTTCAC, A488-ACTGATCCTTGGTTCAC, A488-ACGTCATCTGAATAGTTTelomereN/ATelomeresPNA FISHTelC-Cy3 (F1002, PNA BIO)

Peptide nucleic acid fluorescent in situ hybridization {#s4-11}
------------------------------------------------------

Probes were hybridized according to the manufacturer\'s instructions ([@bib42]). Neuronal nuclei from non-diseased and AD brains were sorted for NeuN positivity and dried onto slides. Slides were washed in PBS, fixed with 4% PFA, and treated with RNase (Qiagen, Valencia, CA) for 20 min at 37°C. Slides were then digested with 200 µg/ml proteinase K (Roche Applied Science, Indianapolis, IN) for 5 min at 37°C. Slides were dehydrated in ethanol series and denatured at 85°C for 5 min. PNA probes in hybridization buffer (20 mM Tris pH 7.4, 60% formamide, 0.1 µg/ml salmon sperm DNA) were then added for 10 min at 85°C. Slides were then removed and placed at room temperature for 2 hr. Slides were then washed twice in 2× SSC + 0.1% tween at 60°C for 30 min each and mounted using progold mounting media. Z-stacks were acquired using a Nikon N-SIM (structured illumination microscopy) super resolution microscope with an Andor iXon3 back-illuminated high sensitivity EMCCD camera with single photon detection capability. Projections were rendered using 3D-SIM Elements software from Nikon. Counts were averaged and analyzed by unpaired, two-tailed t-test
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Genomic mosaicism with increased *APP* copy number in single neurons from sporadic Alzheimer\'s disease brains" for consideration *at eLife*. Your article has been favorably evaluated by a Senior editor, a Reviewing editor, and 3 reviewers.

The following individuals responsible for the peer review of your submission have agreed to reveal their identity: Jeremy Nathans (Reviewing editor), Dimitri Avramopoulos, and Phil Wong (peer reviewers). A further reviewer remains anonymous.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission. I am also including the three reviews in their original form at the end of this letter, as there are many specific and useful suggestions in them that will not be repeated in the summary here.

We would like to request that you resubmit a revised manuscript that addresses the specific issues raised in the reviews below. All three reviewers raised substantive concerns, but the ones that we see as central relate to: ([@bib9]) the comparison of AD vs. normal brains (review \#2), and ([@bib2]) the question of whether the changes in genomic DNA associated with nuclei from AD brains is a cause or consequence of the disease process (review \#1). We recognize that assessing levels of *APP* expression, while logically related to your hypothesis, is not easily done on a single cell level in postmortem brain samples. Even if one assumes that the data is technically sound, there is a major concern that DNA content changes may not be causally related to AD.

A critical discussion of potential artifacts in the data and of the biological interpretation of the data is essential. We note that in the current publishing environment very few authors write truly critical analyses of their experiments. It was not always that way, and *eLife* is trying to restore some balance here. We welcome a critical Discussion section, which we believe enhance the reader\'s ability to judge science. Here is a nice example that illustrates the preceding point: it is from the paper describing the discovery of ubiquitin conjugation as the mark for protein degradation (Hershko A. et al., Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis, PNAS, 1980, April 77 ([@bib48]): 1783-6). After summarizing the evidence that conjugation of APF--1 (=ubiquitin) marks proteins for degradation, the authors write: "Evidence that APF--1-proteins are intermediates in the breakdown of denatured protein as proposed in [Figure 6](#fig6){ref-type="fig"} is indirect and inconclusive at this time."

*Reviewer \#1*:

"The validated pathogenicity of *APP* in familial AD suggested that mosaic alterations in *APP* copy number within single neurons may be a key mechanism for producing sporadic AD. Through the use of five independent experimental approaches, we report increased somatic genomic variation within individual sporadic AD neurons involving mosaic increases in both DNA content and *APP* copy number."

The premise of the manuscript by Bushman et al., as stated above, is to suggest that a mechanistic basis for sporadic Alzheimer\'s disease may be the consequence of increased levels of expression of *APP* in neurons of the cerebral cortex due to mosaic increases in *APP* copy number. The validation of this premise would provide an impetus to further mechanistic studies in AD as well as suggest strategies for therapeutic intervention. Therefore, it is important that the premise be validated in a rigorous manner. There are fundamental challenges to this effort, however. Critical to validation of this premise is the establishment of the presence of the additional *APP* copies in neurons well before the demise of the individual contributing the nuclei of their cortical neurons to the study. An interpretation of the data presented which must be considered is the possibility that the additional DNA present in the nuclei analyzed occurred in the terminal phase of the life of these nuclei shortly before or at the time of death and thus have no direct connection to the pathology experienced by these neurons. Associated with this issue is an understanding of the precise form the observed additional DNA has taken in the analyzed nuclei which would address two questions: first, are complete additional copies of *APP* genomic DNA in fact present in a contiguous fashion and, second, what mechanistic basis might be associated with the occurrence of these additional copies of *APP* DNA. A third approach which might be taken to validate the premise would be to carry out studies directed at evaluating *APP* expression levels in individual neurons to address the presumed pathological consequence of amplification of the *APP* gene in cortical neurons in AD.

The study could have addressed some of these issues but is currently limited in its present form. I will address each of the sets of data presented individually.

[Figure 2](#fig2){ref-type="fig"}: the data shows that a significant number of nuclei contain additional DNA sequences, approximately 7% of additional DNA in a subset of cortical nuclei.

While this reviewer finds the finding that additional DNA is present in a subset of nuclei derived from AD cortex to be persuasive, nothing in the data convinces me that the DNA sequences present in these nuclei were all present in these nuclei at the last point in time that the nuclei were present inside intact neurons. However, this reviewer suggests that the authors carry out whole genome sequencing on a population of nuclei sorted for increased DNA content. What would be the value of such sequencing:

1\) The premise is that *APP* sequences are preferentially increased in copy number. This sequencing should confirm that *APP* gene copy number is increased in these nuclei. The specificity of this increase, and some potential mechanistic insight into the process which produces it, should emerge from an evaluation of what other sequences are increased in copy number besides *APP*.

2\) If intact and functional copies of the *APP* gene are present in the nuclei of the AD cortical neurons examined, then a signature of the mechanistic basis by which the presumed amplification had occurred should be present. This might include the observation of junction sequences between the *APP* gene flanking regions and some other regions in the genome, indications of *APP* gene circularization or other mechanisms that would permit the stable presence of the amplified copies of the *APP* gene to persist in the nuclei of cortical neurons for a substantial period of time.

[Figure 3](#fig3){ref-type="fig"}: Neu-N positive staining is a reasonable criteria for ascertaining that the nuclei under analysis were in fact once present in neuronal cells. It does not, however, establish that at the point in time that additional *APP* gene containing DNA appeared in this nucleus, that the nucleus was present inside an intact cell membrane.

[Figure 4](#fig4){ref-type="fig"}: small pool qPCR assays are consistent with the view that there are increased relative amounts of *APP* gene DNA in the samples derived from AD cortical neurons but give no further insight into how they got there and when. The FISH studies are clear, eliminating the possibility of acquisition of additional complete copies of chromosome 21 as the source of additional *APP* gene copies and establishing the competence of the investigators to carry out two color FISH with genomic DNA probes of significant length.

[Figure 5](#fig5){ref-type="fig"}: these data are consistent with the small pool data for [Figure 4](#fig4){ref-type="fig"}. A useful extension of this data would have been to continue to carry out PCR for DNA sequences beyond exon 3 and exon 14 into the upstream and downstream regions of the *APP* gene. The point is for each case analyzed the size of the DNA segment present in increased copy number is less than an entire chromosome 21 but at least equal in size to the full APP gene transcriptional unit. The DNA samples prepared for this study can easily be quantitated for additional sequences in the *APP* gene region of chromosome 21 to establish where the beginning and end of the genomic sequence of increased copy number is to be found. Are there discrete ends to the increased copy number sequence encompassing exons 3 through 14 of *APP*? If so what might that information tell you about the mechanistic basis for increased copy number?

[Figure 6](#fig6){ref-type="fig"}: the investigators turn to PNA based in situ hybridization to permit visualization of the *APP* genomic sequences exhibiting increased copy number. The authors justify this switch in technology from the techniques used in [Figure 4](#fig4){ref-type="fig"} based on the following statement: "However, conventional point-probe FISH analysis, while useful for aneusomy assessments, cannot quantitatively evaluate copy number changes in single gene loci,..." (Results section).

As I noted above in relation to [Figure 4](#fig4){ref-type="fig"}, this statement is not correct. In fact the author\'s use a 330 kb FISH probe (the approximate size of the *APP* locus) and successfully and accurately assess its copy number in the studies shown in that figure. The use of genomic DNA probes of lengths of 100 kbp or less is and has been routine for in situ hybridization for detecting chromosome rearrangement and breakpoints and copy number for decades. The switch to PNA probes of very limited length adds a layer of concern about the studies shown in [Figure 6](#fig6){ref-type="fig"}. The authors have the capability to do this study as it should be done. A great deal of information on the structure of the extra copies of the *APP* gene can be gained by doing a proper study with conventional genomic DNA probes. They should do this and compare the results of a systematic analysis using probes which extend through and beyond the *APP* gene to address the same questions which can be addressed by extending the PCR based studies to the edges of the *APP* gene and beyond.

In summary, the conceptual basis of these studies is of interest. However, by repeatedly reciting that they have proved the functional significance of their observations by five different methods instead of candidly addressing the limitations of their studies and the possibility that their data may have no bearing whatever on the mechanistic basis of sporadic Alzheimer\'s disease, I find the manuscript unsatisfactory for publication in its present form.

*Reviewer \#2*:

This is a very interesting paper showing evidence in support of brain specific somatic mosaicism for duplications and amplifications of genetic sequences and in particular for the Alzheimer\'s disease (AD) gene *APP*. While *APP* is a known early onset AD gene through both non-synosynous mutations and copy number variation, this work introduces the concept that mosaicism for amplification of *APP* in the cortex could underlie late onset sporadic AD. If true, this represents a very significant progress in our understanding of sporadic AD and given the disease prevalence it can also lead to a major public health impact.

The paper is very well written and easy to understand, the experiments are appropriate and well described, and multiple approaches are used to confirm each result.

Through their work the authors provide convincing evidence that increase in DNA content, which appears to be due to genomic amplifications in many loci including the *APP* gene locus, is a common phenomenon in the cortex, less common in the cerebellum and uncommon in lymphocytes. This is very interesting and indeed provides a possible mechanism for the pathology of sporadic AD. However, no significant evidence is shown to support that this phenomenon is more prevalent in the AD cortex than controls. The presented data do show a somewhat more pronounced effect in AD but the similar, albeit weaker, finding in controls is downplayed, and the data is mostly placed in the supplementary material. Statistical comparisons between case and control brains that could convince the reader that this is indeed more pronounced in AD brains are not provided and would likely not be significant due to the sample size. While it is likely that there is a true difference, the authors should be more cautious about making statements of "mosaicism in AD brains", which implies that this is not the case in controls. They should also provide more discussion on the fact that this is also observed in cases. While this phenomenon provides a substrate that might be necessary or just facilitate the development of plaques in AD, based on the authors own data it is likely not sufficient. These points should be made in the Discussion.

The manuscript would also benefit from more discussion on the significant differences between lymphocytes, cerebellum and cortex. It seems perhaps counter intuitive that cells that undergo many divisions throughout life maintain their DNA content much better than cells that do not, and some discussion on this would be useful in better understanding the results and their potential impact.

*Reviewer \#3*:

By exploiting the observation that individual neurons in brains display somatic genomic mosaicism, Bushman et al. showed such phenomenon of increases in DNA content and specific elevation of copy number of the *APP* gene occurred in single neurons from affected regions of cases of sporadic Alzheimer\'s disease (AD). These novel findings would have important implications for *APP* gene dosage as a critical determinant of sporadic AD, for which its etiology remain largely elusive.

While the authors provide a set of compelling evidence using state of the art approaches to support their conclusion, one assumption is that the increase of up to 12 copies of *APP* gene in neurons from AD are all functional and active genes. As previous work has documented that the coding region of human APP gene spans ∼400 kb of genomic DNA (Rooke et al., Mamm. Genome, 4:662-9, 1993), it is possible that the increase in *APP* gene copy number in neurons from AD cases do not represent active full length *APP* genes. Direct evidence to distinguish whether active full length copies of *APP* gene from inactive non-transcribed pseudogenes account for the increase in gene copy number in neurons will strengthen this manuscript. For example, is there any evidence that the *APP* transcript (as judged by in situ rtPCR using RNAscope technology) is increased in these neurons with elevation in copy number of *APP* gene? Positive data will strongly support the notion that the increase in amyloid burden can be attributable to the increase in number of active *APP* gene in neurons within affected regions of sporadic AD patients.

10.7554/eLife.05116.031

Author response

*We would like to request that you resubmit a revised manuscript that addresses the specific issues raised in the reviews below. All three reviewers raised substantive concerns, but the ones that we see as central relate to: (*[@bib9]*) the comparison of AD vs. normal brains (review \#2), and (*[@bib2]*) the question of whether the changes in genomic DNA associated with nuclei from AD brains is a cause or consequence of the disease process (review \#1). We recognize that assessing levels of* APP *expression, while logically related to your hypothesis, is not easily done on a single cell level in postmortem brain samples. Even if one assumes that the data is technically sound, there is a major concern that DNA content changes may not be causally related to AD.*

The first major concern was the comparison of AD vs. normal brains (i.e., case vs. control): this has now been addressed by experimentally increasing the N for non-diseased brains (11 new brains), controlled by repeats of AD samples from the original cohort, to improve statistical power of our data. Increased significance was achieved to differentiate diseased vs. non-diseased cortical samples (P=0.0034). In addition, we also pursued meta-data analysis of previously analyzed, non-diseased cortical samples to still further increase the "N" of non-diseased samples, towards better assessing statistical separation between non-diseased and diseased samples. This approach was made possible by use of an independent, previously assessed age-matched cohort of non-diseased brains that had been studied using precisely the same protocols and flow cytometry equipment (from [@bib74]) as that used in the current manuscript, whereby raw data from flow cytometry were re-analyzed identically to: 1) the previous data of the first submission and 2) new data processed in response to the review. These meta-data points are distinguished by distinct icons in new [Figure 3](#fig3){ref-type="fig"}. Notably, new samples without meta-data demonstrate statistical significance (P=0.0034), and with inclusion of the meta-data, even more statistical significance (P=0.0001). These data demonstrate statistical separation between AD vs. non-diseased cortex. Further details are provided in the point-by-point critique.

The second concern related to DNA content and causality is clearly of great import, yet also extremely difficult to address experimentally in human post-mortem studies. Further research will be necessary in order to answer "chicken or egg" questions, as well as those related to function and pathogenicity: an historical case in point is ApoE that was identified as an AD risk factor over 20 years ago yet for which function and mechanistic pathogenicity is still not completely understood. Similarly, even in the case of familial forms of AD involving defined heritable gene mutations present throughout life, decades are still required for the clear manifestation of disease, thus underscoring our incomplete understanding of even well studied pathogenic AD genes like *APP*.

To acknowledge this deficiency in understanding that extends from familial disease through our current report, we have now both softened the writing throughout the paper and have added a discussion of our study's limitations.

*A critical discussion of potential artifacts in the data and of the biological interpretation of the data is essential. We note that in the current publishing environment very few authors write truly critical analyses of their experiments. It was not always that way, and* eLife *is trying to restore some balance here. We welcome a critical Discussion section, which we believe enhance the reader\'s ability to judge science. Here is a nice example that illustrates the preceding point: it is from the paper describing the discovery of ubiquitin conjugation as the mark for protein degradation (Hershko A. et al., Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis, PNAS, 1980, April 77 (4): 1783-6). After summarizing the evidence that conjugation of APF-1 (=ubiquitin) marks proteins for degradation, the authors write: "Evidence that APF-1-proteins are intermediates in the breakdown of denatured protein as proposed in* [*Figure 6*](#fig6){ref-type="fig"} *is indirect and inconclusive at this time."*

We welcome the opportunity to provide a critical Discussion section and have now added this into the text.

Reviewer \#1:

*"The validated pathogenicity of* APP *in familial AD suggested that mosaic alterations in* APP *copy number within single neurons may be a key mechanism for producing sporadic AD. Through the use of five independent experimental approaches, we report increased somatic genomic variation within individual sporadic AD neurons involving mosaic increases in both DNA content and* APP *copy number."*

*The premise of the manuscript by Bushman et al., as stated above, is to suggest that a mechanistic basis for sporadic Alzheimer\'s disease may be the consequence of increased levels of expression of* APP *in neurons of the cerebral cortex due to mosaic increases in* APP *copy number. The validation of this premise would provide an impetus to further mechanistic studies in AD as well as suggest strategies for therapeutic intervention. Therefore, it is important that the premise be validated in a rigorous manner. There are fundamental challenges to this effort, however. Critical to validation of this premise is the establishment of the presence of the additional* APP *copies in neurons well before the demise of the individual contributing the nuclei of their cortical neurons to the study. An interpretation of the data presented which must be considered is the possibility that the additional DNA present in the nuclei analyzed occurred in the terminal phase of the life of these nuclei shortly before or at the time of death and thus have no direct connection to the pathology experienced by these neurons.*

We thank the reviewer for his/her comments. We believe that it is most unlikely that the observed changes in both increased DNA content and increased *APP* copy number are artifacts of death, unrelated to pathology, for multiple reasons:

1\) If the changes were non-specifically occurring "before or at the time of death," DNA degradation should be observed (e.g*.,* nucleosomal "ladders" seen with apoptosis, or genomic DNA degradation seen with sub-optimal post-mortem intervals). The opposite was observed.

2\) Similarly, by the critique's hypothesis, the same degradative phenomenon would have been expected to be observed in non-diseased brains. By contrast, there was statistically significant separation between non-diseased and diseased samples (prior version and new [Figure 3](#fig3){ref-type="fig"}).

3\) Critically, postulated changes produced by death would be expected to occur uniformly, in all parts of the brain from the same individual. By contrast, the cerebellum always showed less of an effect compared to the cortex in the same individual.

DNA content variation and *APP* copy number increases were also observed, albeit to a lesser extent, in non-diseased samples: our samples were from aged individuals (average age, 82.5 years) supporting the possibility that genomic changes in non-diseased cells might represent a pre-morbid state in some individuals, although this is impossible to prove using post-mortem analyses. However, our data are consistent with the documented presence of senile plaques in normal aged brains (since we observe some *APP* CNVs there), as well as the universal presence of senile plaques in sporadic AD despite no obvious germ line alterations to *APP* or increases in constitutive *APP* copy number.

*Associated with this issue is an understanding of the precise form the observed additional DNA has taken in the analyzed nuclei which would address two questions: first, are complete additional copies of* APP *genomic DNA in fact present in a contiguous fashion and, second, what mechanistic basis might be associated with the occurrence of these additional copies of* APP *DNA.*

We have begun to investigate this more thoroughly, being of absolute interest. However, a comprehensive assessment of all DNA differences, including a demonstration of their pathogenicity, along with the mechanisms that cause genomic mosaicism in neurons (e.g*.,* how and when) is a monumental undertaking, especially in trying to establish statistically significant linkage to any identified sequence differences. We currently have two key hints regarding the "form" of additional DNA copies. First, our single cell qPCR data show a high, but notably non-identical, concordance rate between the two assessed *APP* exons that are separated by 170 Kb, suggesting that the full coding region of *APP* could be amplified rather than only individual exons, although the latter is a non-mutually exclusive possibility as well. The data are thus consistent with increases in the *APP* coding region, along with partial amplification involving one or the other of the two exons. Critically, our PNA-FISH data identify quantitative, often single signals within a nucleus, supporting *APP* amplification within a physically constrained locus.

*A third approach which might be taken to validate the premise would be to carry out studies directed at evaluating* APP *expression levels in individual neurons to address the presumed pathological consequence of amplification of the* APP *gene in cortical neurons in AD.*

Please see response to Review \#3.

*The study could have addressed some of these issues but is currently limited in its present form. I will address each of the sets of data presented individually*.

[*Figure 2*](#fig2){ref-type="fig"}*: the data shows that a significant number of nuclei contain additional DNA sequences, approximately 7% of additional DNA in a subset of cortical nuclei*.

*While this reviewer finds the finding that additional DNA is present in a subset of nuclei derived from AD cortex to be persuasive, nothing in the data convinces me that the DNA sequences present in these nuclei were all present in these nuclei at the last point in time that the nuclei were present inside intact neurons*.

Our data argue for the DNA being present before and unrelated to the technique of nuclear isolation. We would like to clarify the methods used. Whole brain tissue (with intact neurons and glia) was first triturated on ice in an NP40-containing buffer used to isolate all brain nuclei. New [Figures 2 and 3](#fig2 fig3){ref-type="fig"} (old [Figure 2](#fig2){ref-type="fig"}) describe the DNA content shift of whole brain nuclei stained for propidium iodide, while (now) [Figure 4](#fig4){ref-type="fig"} demonstrates that upon immunolabeling of these nuclei for a highly validated neuronal marker, NeuN, the right shifted nuclei are largely neurons. We do not believe that DNA would accumulate within nuclei after they have been isolated for multiple reasons:

1\) As noted above, degradative processes degrade DNA rather than produce more synthesis.

2\) Isolated nuclei were fixed in seconds following trituration, with 2% paraformaldehyde (and other fixatives have been tried), producing the same results as unfixed samples, and do not support active enzymatic synthesis associated with nuclei isolation methods.

3\) Similarly, neurons (NeuN-positive nuclei) have more DNA compared to non-neuronal cells (NeuN-negative) from the same cortical sample, arguing against a generic artifact affecting all isolated nuclei.

4\) Hypothesized DNA synthesis after isolation is not consistent with its relative absence in cerebellar neurons from the same individual, as compared to the prefrontal cortical neurons, arguing against a non-specific phenomenon that increases DNA content with nuclear isolation.

5\) Published work ([@bib76]) demonstrated increased DNA content by fluorescence quantitation of centromere sequences (CENP-B box) in single nuclei, consistent with genomic origins of the DNA (rather than other sources like mitochondria or bacterial contamination): these studies were also pursued on fixed nuclei.

However, this reviewer suggests that the authors carry out whole genome sequencing on a population of nuclei sorted for increased DNA content. What would be the value of such sequencing:

*1) The premise is that* APP *sequences are preferentially increased in copy number. This sequencing should confirm that* APP *gene copy number is increased in these nuclei. The specificity of this increase, and some potential mechanistic insight into the process which produces it, should emerge from an evaluation of what other sequences are increased in copy number besides* APP*.*

*2) If intact and functional copies of the* APP *gene are present in the nuclei of the AD cortical neurons examined, then a signature of the mechanistic basis by which the presumed amplification had occurred should be present. This might include the observation of junction sequences between the* APP *gene flanking regions and some other regions in the genome, indications of* APP *gene circularization or other mechanisms that would permit the stable presence of the amplified copies of the* APP *gene to persist in the nuclei of cortical neurons for a substantial period of time.*

We absolutely agree with the reviewer that sequencing of an appropriate template---single cell or cohort population (as suggested---could provide important information on copy number and junctional sequences, and we are endeavoring to identify the appropriate template, which turns out to be difficult because of both biological challenges associated with mosaicism, and technical challenges of single-cell sequencing. Some details underscoring the challenges:

1\) The inherent nature of mosaicism is that a population consists of a complex mixture of templates consisting predominantly of germline sequences intermixed with myriad mutant templates (based upon data in our manuscript showing diverse *APP* copies by qPCR and PNA FISH indicative of diverse genomic structures). Bulk sequencing of such a population will report a normal genome, since the rare mutants would be swamped by the germline sequence of unaffected cells as well as the normal allele in a mutant cell. Also, sequencing of mosaic templates does not lend itself to routine CNV calling, as current algorithms (e.g., those used by Illumina) are not capable of making reliable calls on complex, mosaic templates.

2\) The reviewer suggests sequencing sorted nuclei to identify full-length *APP* copy number changes or perhaps flanking sequences towards assessing mechanisms of CNV generation. At this time, it is not possible to obtain enough nuclei known to contain specific genomic changes, even assuming that a stereotyped change exists. Moreover, such relatively rare nuclei would require amplification to achieve sufficient sequencing depths to identify mechanistic signatures like flanking sequence changes. Amplification of the template greatly increases noise, and decreases the ability to call copy numbers with certainty.

3\) Some groups, including our own, have begun to work out the steps necessary for identifying mosaic changes in single neurons using sequencing [@bib45]; [@bib28]; [@bib11]). However, this technique also has many challenges including: amplification error, extremely low depth (at best a ∼0.025X coverage), a resolution of 2-10 Mb (the *APP* locus is ∼0.3 Mb), as well as inconsistencies in the methods used that limit comparisons between studies, such as different cell and/or nuclei isolation protocols, multiple amplification techniques, and multiple informatics analysis pipelines. Such challenges will likely be overcome in the future, but cannot be met currently with the available technology.

Biological mosaicism and technological limitations on sequencing therefore prevent rigorous copy-number analyses as well as reliable junctional sequence data. However, we believe our current study provides data that represent a starting point for now understanding the sequence changes underlying DNA content variability in a neurodegenerative disease affecting a specific, highly validated AD gene, *APP,* and we expect future studies to sort-out many of these problems.

[*Figure 3*](#fig3){ref-type="fig"}*: Neu-N positive staining is a reasonable criteria for ascertaining that the nuclei under analysis were in fact once present in neuronal cells. It does not, however, establish that at the point in time that additional APP gene containing DNA appeared in this nucleus, that the nucleus was present inside an intact cell membrane*.

We interpret this part of the critique as proposing a process whereby additional *APP* copies would be produced in isolated nuclei, once outside of the cell. The overall issue was discussed in response to the [Figure 2](#fig2){ref-type="fig"} data critique, whereby degradative processes should degrade DNA and be non-specific to thus affect all samples uniformly, which was not the case. This same argument extends to *APP* copies, and once again, we observe comparatively selective increases in the AD cortex that are statistically distinct from the cerebellar cells of the same individual, as well as in both cortex and cerebellum of the non-diseased brain. We therefore believe that increases in *APP* copies are not artifacts of nuclear isolation.

[*Figure 4*](#fig4){ref-type="fig"}*: small pool qPCR assays are consistent with the view that there are increased relative amounts of* APP *gene DNA in the samples derived from AD cortical neurons but give no further insight into how they got there and when. The FISH studies are clear, eliminating the possibility of acquisition of additional complete copies of chromosome 21 as the source of additional* APP *gene copies and establishing the competence of the investigators to carry out two color FISH with genomic DNA probes of significant length.*

Establishing *when* and *how* additional DNA including copies of *APP* appeared in the nucleus is not feasible using post-mortem human tissue and is beyond the scope of this study, although this is of absolute future interest.

[*Figure 5*](#fig5){ref-type="fig"}*: these data are consistent with the small pool data for* [*Figure 4*](#fig4){ref-type="fig"}*. A useful extension of this data would have been to continue to carry out PCR for DNA sequences beyond exon 3 and exon 14 into the upstream and downstream regions of the* APP *gene. The point is for each case analyzed the size of the DNA segment present in increased copy number is less than an entire chromosome 21 but at least equal in size to the full* APP *gene transcriptional unit. The DNA samples prepared for this study can easily be quantitated for additional sequences in the* APP *gene region of chromosome 21 to establish where the beginning and end of the genomic sequence of increased copy number is to be found. Are there discrete ends to the increased copy number sequence encompassing exons 3 through 14 of* APP*? If so what might that information tell you about the mechanistic basis for increased copy number?*

We agree with the reviewer that this could have been a useful experiment, and such information could provide useful mechanistic insight. Unfortunately, the entire DNA template is consumed in the single-cell Biomark HD qPCR reaction, preventing us from conducting further analyses of the cells already interrogated. We will continue analyses as we improve cell selection strategies in future work, but cannot address this particular issue in the current manuscript.

[*Figure 6*](#fig6){ref-type="fig"}*: the investigators turn to PNA based* in situ *hybridization to permit visualization of the* APP *genomic sequences exhibiting increased copy number. The authors justify this switch in technology from the techniques used in* [*Figure 4*](#fig4){ref-type="fig"} *based on the following statement: "However, conventional point-probe FISH analysis, while useful for aneusomy assessments, cannot quantitatively evaluate copy number changes in single gene loci..." (Results section)*.

*As I noted above in relation to* [*Figure 4*](#fig4){ref-type="fig"}*, this statement is not correct. In fact the author\'s use a 330 kb FISH probe (the approximate size of the* APP *locus) and successfully and accurately assess its copy number in the studies shown in that figure. The use of genomic DNA probes of lengths of 100 kbp or less is and has been routine for* in situ *hybridization for detecting chromosome rearrangement and breakpoints and copy number for decades. The switch to PNA probes of very limited length adds a layer of concern about the studies shown in* [*Figure 6*](#fig6){ref-type="fig"}*. The authors have the capability to do this study as it should be done. A great deal of information on the structure of the extra copies of the* APP *gene can be gained by doing a proper study with conventional genomic DNA probes. They should do this and compare the results of a systematic analysis using probes which extend through and beyond the* APP *gene to address the same questions which can be addressed by extending the PCR based studies to the edges of the* APP *gene and beyond.*

We believe that there is some confusion over what we meant by quantifying copy number, which explains our development and use of PNA-FISH. Several points should be considered:

1\) Conventional point-probe FISH, as noted in the review and as we used to interrogate trisomy 21 (old [Figure 4](#fig4){ref-type="fig"}, now [Figure 5](#fig5){ref-type="fig"}), cannot evaluate copy number changes if those changes are occurring as contiguous copies in close proximity to one another. This reflects multiple factors including: the probe itself, that consists of many fluorescently labeled fragments that can have varied melting temperatures (e.g., GC-rich regions); unknown efficiency of fluorochrome conjugation; unknown relationship of a fluorochrome to a given fragment; resonance energy quenching of fluorescence by neighboring fluors; unknown intact state of the targeted locus; etc. One can count fluorescent "dots" on chromosomes, which is routinely done for FISH (and which we used to interrogate chromosome 21), but this approach cannot quantitatively report (in a reliable way) template copies---e.g., multiple copies of a target---within a single dot. Moreover, routine FISH typically uses microscopy that is non-quantitative vs. the SIM approach that we employed.

2\) By contrast, PNA FISH provides single-nucleotide sequence specificity and quantitative capabilities. Each PNA probe was designed to limit resonance quenching, and each probe contains only one fluor (Alexa 488). This provided the capability to quantify the fluorescence within a single dot when combined with SIM. PNA-FISH is a validated technology for quantitating telomeric repeats, and moreover, our controls demonstrate specificity for the targeted APP exons as well as the expected quantitative, linear behavior in detecting DNA copies (now [Figure 7--figure supplement 1](#fig7s1){ref-type="fig"}). In addition, PNA-FISH has been used for other genomic loci including CENP-B (Chen et al., 1999, and [@bib76]), alpha satellite domains (Chen et al., 2000), and CAG repeats (Brind'Amour et al., 2012). It is this quantitative information to which we refer: it is fundamentally different from the standard of counting dots as evidence of copies for a single allele, and cannot be approached using standard FISH probes.

3\) As importantly, unlike standard FISH, our PNA probes could be and were designed against the same exons as those interrogated by single-cell qPCR, and notably, both techniques produced similar-appearing distributions of differential copy numbers.

4\) In view of a) the extensive literature utilizing quantitative PNA techniques to identify genomic loci, b) the specificity and quantitative controls provided in [Figure 7--figure supplement 1](#fig7s1){ref-type="fig"} (old [Figure 6--figure supplement 1](#fig6s1){ref-type="fig"}), c) the concordance between our PNA-FISH data and qPCR data, and d) the internal consistency of our data that rules out trisomy 21 as increased in AD (and is therefore consistent with local amplification), we believe the employed assay is appropriate and not interchangeable or replaceable by standard genomic FISH.

5\) Finally, it is also important to note that PNA-FISH, unlike all single-cell sequencing and qPCR techniques, provides a copy number assessment without the use of genomic amplification.

We have also now addressed the regions in the text that required clarification for our use of PNA-FISH.

*In summary, the conceptual basis of these studies is of interest. However, by repeatedly reciting that they have proved the functional significance of their observations by five different methods instead of candidly addressing the limitations of their studies and the possibility that their data may have no bearing whatever on the mechanistic basis of sporadic Alzheimer\'s disease, I find the manuscript unsatisfactory for publication in its present form*.

In response to the reviewer comments we have toned-down our assertion that *APP* copy number increases are a pathogenic mechanism and added a critical discussion assessing the limitations of our study. We, like the reviewer, are very interested in the mechanism of mosaic changes, however this is well beyond the scope of this study. Our study is primarily descriptive in nature, as are virtually all studies limited to working with post-mortem AD brains that reflect a progeric human disease requiring decades to manifest. Importantly, any novel process or gene that may underlie mosaicism, while enormously interesting, could not be proven to underlie sporadic AD without decades of prospective human population and/or clinical trials to test a relevant hypothesis. Therefore, requests for a molecular mechanism beyond validated *APP* represent, in our opinion, an unreasonably high bar for publication on a new phenomenon as we report here. As noted in the second major point identified in the cover letter from the editors, we have toned-down our claims by highlighting the possibility that alterations in DNA content variation and increased *APP* copy number may not be a cause of sporadic AD.

Reviewer \#2:

*\[...\] Through their work the authors provide convincing evidence that increase in DNA content, which appears to be due to genomic amplifications in many loci including the* APP *gene locus, is a common phenomenon in the cortex, less common in the cerebellum and uncommon in lymphocytes. This is very interesting and indeed provides a possible mechanism for the pathology of sporadic AD. However, no significant evidence is shown to support that this phenomenon is more prevalent in the AD cortex than controls. The presented data do show a somewhat more pronounced effect in AD but the similar, albeit weaker, finding in controls is downplayed, and the data is mostly placed in the supplementary material. Statistical comparisons between case and control brains that could convince the reader that this is indeed more pronounced in AD brains are not provided and would likely not be significant due to the sample size.*

We thank the reviewer for these suggestions and, as discussed at the start of this rebuttal, have now added new experimental data consisting of new brain samples as well as re-analyses of previously published data (meta data) that, taken independently or combined together, increase the statistical significance values (P=0.0001) between non-diseased and AD samples; these were noted above in response to the first major issue of the cover letter, and new data are provided in the new [Figures 2 and 3](#fig2 fig3){ref-type="fig"} (old [Figure 2](#fig2){ref-type="fig"} and [Figure 2--figure supplement 1](#fig2s1){ref-type="fig"}). Our new data demonstrate statistically significant differences between case and control.

*While it is likely that there is a true difference, the authors should be more cautious about making statements of "mosaicism in AD brains", which implies that this is not the case in controls. They should also provide more discussion on the fact that this is also observed in cases. While this phenomenon provides a substrate that might be necessary or just facilitate the development of plaques in AD, based on the authors own data it is likely not sufficient. These points should be made in the Discussion*.

We thank the reviewer for this critical assessment of the data and we have toned down our statements in our revised Discussion, as noted in response to the other reviews.

*The manuscript would also benefit from more discussion on the significant differences between lymphocytes, cerebellum and cortex. It seems perhaps counter intuitive that cells that undergo many divisions throughout life maintain their DNA content much better than cells that do not, and some discussion on this would be useful in better understanding the results and their potential impact*.

We have now included further discussion on this topic. DNA content changes have been examined in a limited number of tissue types, cell types, and conditions. It is important to note that the interrogated neurons are likely terminal in their fate: they will not divide further, contrasting with lymphocytes. Populations of cells, like lymphocytes "that undergo many divisions" are those that have been selected to be capable of continuing cell division, as seen in stem and progenitor populations, which are not found amongst neurons that are, by definition, post-mitotic. We think it is likely that many dividing cells that deviate significantly from the germline genome---and thus would be incapable of further division---are eliminated by cell death and would not be in the population interrogated for DNA content. Support for this view includes our reports on aneuploidies in neuroprogenitor cells ([@bib51]; [@bib6], [@bib7]), whereby the most extreme forms appear to be eliminated by caspase-mediated cell death.

Reviewer \#3:

*\[...\] While the authors provide a set of compelling evidence using state of the art approaches to support their conclusion, one assumption is that the increase of up to 12 copies of* APP *gene in neurons from AD are all functional and active genes. As previous work has documented that the coding region of human APP gene spans ∼400 kb of genomic DNA (Rooke et al., Mamm. Genome, 4:662-9, 1993), it is possible that the increase in* APP *gene copy number in neurons from AD cases do not represent active full length* APP *genes. Direct evidence to distinguish whether active full length copies of* APP *gene from inactive non-transcribed pseudogenes account for the increase in gene copy number in neurons will strengthen this manuscript. For example, is there any evidence that the* APP *transcript (as judged by* in situ *rtPCR using RNAscope technology) is increased in these neurons with elevation in copy number of* APP *gene? Positive data will strongly support the notion that the increase in amyloid burden can be attributable to the increase in number of active* APP *gene in neurons within affected regions of sporadic AD patients.*

We absolutely agree that these data would be of high interest, but also note several technical and conceptual issues that we believe limit the feasibility and interpretation of the experiment.

1\) Genetic linkage of *APP* gains in some forms of familial AD and Down syndrome are clear, however the mechanisms through which this gain produces AD remain unclear, including at a transcriptional level. Our data in fact argue that there are likely to be myriad additional changes to the genome and genes produced by cortical increases in DNA content that represent, on average, hundreds of megabases of additional sequence. It is also a fact that all forms of AD are progeric: even in familial cases, it takes decades to manifest despite the germline presence (for familial disease) of the "causative" gene mutation. We believe that it is likely that *APP* gene expression will be increased at some point in the life cycle of an affected AD neuron, however this could occur early in life, or perhaps at the terminal phase of neuronal life---AD is a neurodegenerative disease---which might prevent us from interrogating those neurons with high levels of gene transcription since they would be eliminated by death. This further raises the issue of when, as well as where, one should look for transcriptional changes. It is further possible that there are heterogeneous responses of individual neurons to increased *APP* copy number that may or may not involve increased gene transcription. Moreover, we also see increases in *APP* gene copy number in rarer non-diseased neurons, raising the issue of how to interpret the obtained data from AD neurons, especially in a statistically significant manner related to pathogenesis. At this juncture, the genetic linkage with familial AD combined with our mosaic data provides a plausible explanation, with both disease forms awaiting cell and molecular mechanistic detail.

2\) It is also notable that sporadic AD has an onset decades later than the changes seen in Down syndrome, which contains a single additional copy (in all cells). We are unable to find reports of quantitative *APP* RNA expression in single Down syndrome cells, but are certain there is not uniform expression in all cells that contain the additional copy, underscoring issues of how one interprets the presence or absence of a transcriptional signal in neurons with varied *APP* copy number.

3\) As importantly from a technical standpoint, it is not currently possible to identify simultaneously, in a single AD neuron (which is the appropriate goal), genomic amplification of *APP* and mRNA from the same locus. Technological approaches in the future should allow this to be realized.

4\) RNAscope is an intriguing idea, however recent discussions with the manufacturer indicate that its application for genomic loci is unproven, as is its use for RNA within a nucleus that contains perhaps 5% or less of the mRNA that one would want to interrogate. That said, future studies may well provide new insights via RNAscope. In our hands, in situ PCR has not proven reliable or quantitative, and this is not a technology that we currently view as appropriate for the questions at hand.

5\) Additionally, the full length *APP* gene is ∼298 Kb, while the two exons used in this study are separated by ∼170 Kb. Using single cell qPCR on the Biomark HD, a concordance rate of ∼85% was seen between the two exons. This suggests that, minimally, most of the gene is amplified. How this relates to individual neurons at distinct points of their life cycle and location within the brain (as well as specific neuronal subtype) again remains for future work.

Thus, we are enthusiastic about future analyses stemming from the observations of this manuscript, but believe that garnered information as proposed in this critique would not change the basic result, and obtaining such data would require a very significant effort beyond the scope of the current study.
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